Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development

Advanced Drug Delivery Reviews

Volumn 63, Issue 13, 2011, Pages 1118-1159

  Kamerzell, Tim J ^a   Esfandiary, Reza ^b   Joshi, Sangeeta B ^b   Middaugh, C Russell ^b   Volkin, David B ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Biophysical; Excipient; Formulation; High throughput screening; Interaction; Protein; Stability

Indexed keywords

BIOPHYSICAL; EXCIPIENT; FORMULATION; HIGH THROUGHPUT SCREENING; INTERACTION;

BIOPHYSICS; DRUG DOSAGE; DRUG INTERACTIONS; DRUG PRODUCTS; HYDROGEN BONDS; THROUGHPUT;

PROTEINS;

AMINO ACID; ANTIOXIDANT; ARGININE; BUFFER; CARBOHYDRATE DERIVATIVE; CHELATING AGENT; DEOXYRIBONUCLEASE I; EXCIPIENT; FIBROBLAST GROWTH FACTOR; GLYCEROL; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS A VACCINE; INSULIN; INTERFERON; INTERLEUKIN 2; LIGAND; MONOCLONAL ANTIBODY; POLIOMYELITIS VACCINE; POLYANION; POLYMER; POLYOL; PRESERVATIVE; PROTEIN; SODIUM CHLORIDE; SOLVENT; SUGAR; SURFACTANT; UNINDEXED DRUG; UREA; VACCINE;

BINDING KINETICS; BIOPHYSICS; CALORIMETRY; CHEMICAL ANALYSIS; CRYSTALLIZATION; DIGITAL IMAGING; DISPERSION; DRUG FORMULATION; DRUG STABILITY; FREEZING; GELATION; HYDRATION; HYDROGEN BOND; IONIC STRENGTH; MICROSCOPY; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PH; PHASE SEPARATION; PHASE TRANSITION; PRIORITY JOURNAL; REVIEW; SPECTROSCOPY; STATIC ELECTRICITY; STATISTICAL ANALYSIS;

DRUG DESIGN; DRUG STABILITY; EXCIPIENTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYDROGEN BONDING; PROTEINS; STATIC ELECTRICITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 80054717076     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.07.006     Document Type: Review

References (559)

1. Akers M.J. Excipient-drug interactions in parenteral formulations. J. Pharm. Sci. 2002, 91:2283-2300.
2. Akers M.J., Vasudevan V., Stickelmeyer M. Formulation development of protein dosage forms. Pharm. Biotechnol. 2002, 14:47-127.
3. Parkins D.A., Lashmar U.T. The formulation of biopharmaceutical products. Pharm. Sci. Technol. Today 2000, 3:129-137.
4. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 1999, 185:129-188.
5. Jorgensen L., Hostrup S., Moeller E.H., Grohganz H. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. Expert Opin. Drug Deliv. 2009, 6:1219-1230.
6. Nema S., Washkuhn R.J., Brendel R.J. Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 1997, 51:166-171.
7. Powell M.F., Nguyen T., Baloian L. Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 1998, 52:238-311.
8. Katdare A., Chaubal M.V. Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems 2006, Informa Healthcare.
9. Maddux N.R., Josh S.B., Volkin D.B., Ralston J., Middaugh C.R. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J. Pharm. Sci. 2011, 100:4171-4179.
10. Joshi S.B., Bhambhani A., Zeng Y., Middaugh C.R. An Empirical Phase Diagram-High-Throughput Screening Approach to the Characterization and Formulation of Biopharmaceuticals 2010, John Wiley and Sons.
11. Gibson T.J., McCarty K., McFadyen I.J., Cash E., Dalmonte P., Hinds K.D., Dinerman A.A., Alvarez J.C., Volkin D.B. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. J. Pharm. Sci. 2011, 100:1009-1021.
12. Goldberg D.S., Bishop S.M., Shah A.U., Sathish H.A. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. J. Pharm. Sci. 2011, 100:1306-1315.
13. He F., Phan D.H., Hogan S., Bailey R., Becker G.W., Narhi L.O., Razinkov V.I. Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J. Pharm. Sci. 2010, 99:2598-2608.
14. Li Y., Mach H., Blue J.T. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. J. Pharm. Sci. 2011, 100:2120-2135.
15. Kishore R.S., Kiese S., Fischer S., Pappenberger A., Grauschopf U., Mahler H.C. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics. Pharm. Res. 2011, 28:1194-1210.
16. Kishore R.S., Pappenberger A., Dauphin I.B., Ross A., Buergi B., Staempfli A., Mahler H.C. Degradation of polysorbates 20 and 80: studies on thermal autoxidation and hydrolysis. J. Pharm. Sci. 2011, 100:721-731.
17. Abernethy D.R., Destefano A.J., Cecil T.L., Zaidi K., Williams R.L. Metal impurities in food and drugs. Pharm. Res. 2010, 27:750-755.
18. Wasylaschuk W.R., Harmon P.A., Wagner G., Harman A.B., Templeton A.C., Xu H., Reed R.A. Evaluation of hydroperoxides in common pharmaceutical excipients. J. Pharm. Sci. 2007, 96:106-116.
19. Malyala P., Singh M. Endotoxin limits in formulations for preclinical research. J. Pharm. Sci. 2008, 97:2041-2044.
20. Lubiniecki A.S., Shadle P.J. Raw material considerations. Dev. Biol. Stand. 1997, 91:65-72.
21. Pifferi G., Santoro P., Pedrani M. Quality and functionality of excipients. Farmaco 1999, 54:1-14.
22. Robertson M.I. Regulatory issues with excipients. Int. J. Pharm. 1999, 187:273-276.
23. Guidance for Industry-Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients, Food and Drug Administration (FDA) 2005.
24. Guideline on Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product, European Medicines Agency (EMEA) 2007.
25. Bolton G.R., Boesch A.W., Basha J., Lacasse D.P., Kelley B.D., Acharya H. Effect of protein and solution properties on the Donnan effect during the ultrafiltration of proteins. Biotechnol. Prog. 2011, 27:140-152.
26. Stoner M.R., Fischer N., Nixon L., Buckel S., Benke M., Austin F., Randolph T.W., Kendrick B.S. Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations. J. Pharm. Sci. 2004, 93:2332-2342.
27. Teeters M., Bezila D., Benner T., Alfonso P., Alred P. Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies. Biotechnol. Bioeng. 2011, 108:1338-1346.
28. Cauchy M., Hefford M.A. Excipient exchange in the comparison of preparations of the same biologic made by different manufacturing processes: an exploratory study with recombinant human growth hormone (rhGH). Biologicals 2010, 38:637-643.
29. Golightly L.K., Smolinske S.S., Bennett M.L., Sutherland E.W., Rumack B.H. Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I). Med. Toxicol. Adverse Drug Exp. 1988, 3:128-165.
30. Jakel D., Keck M. Purity of excipients. Excipient Toxicity and Safety Drugs and the Pharmaceutical Sciences v.103 2000, 21-58. M. Dekker, New York. M.L. Weiner, L.A. Kotkoskie (Eds.).
31. Chen M.L. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv. Drug Deliv. Rev. 2008, 60:768-777.
32. Gaynor P.M., Bonnette R., Garcia E., Kahl L., Valerio L. FDA's approach to the GRAS provision: a history of processes. FDA Science Forum 2006.
33. GRAS Substances Database http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/GRASSubstancesSCOGSDatabase/default.htm.
34. Inactive Ingredient Search for Approved Drug Products, http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm.
35. Rowe R.C., Sheskey P.J., Owen S.C. The Handbook of Pharmaceutical Excipients 2005, APhA Publications. 5th ed.
36. Maclean D.S., Qian Q., Middaugh C.R. Stabilization of proteins by low molecular weight multi-ions. J. Pharm. Sci. 2002, 91:2220-2229.
37. Apte S.P., Ugwu S.O. A review and classification of emerging excipients in parenteral medications. Pharm. Technol. March 2003, 46-60.
38. Lentzen G., Schwarz T. Extremolytes: natural compounds from extremophiles for versatile applications. Appl. Microbiol. Biotechnol. 2006, 72:623-634.
39. Stoll V.S., Blanchard J.S. Buffers: principles and practice. Methods Enzymol. 1990, 182:24-38.
40. Zheng J.Y., Janis L.J. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int. J. Pharm. 2006, 308:46-51.
41. Katayama D.S., Nayar R., Chou D.K., Valente J.J., Cooper J., Henry C.S., Vander Velde D.G., Villarete L., Liu C.P., Manning M.C. Effect of buffer species on the thermally induced aggregation of interferon-tau. J. Pharm. Sci. 2006, 95:1212-1226.
42. Piedmonte D.M., Treuheit M.J. Formulation of Neulasta (pegfilgrastim). Adv. Drug Deliv. Rev. 2008, 60:50-58.
43. Esue O., Kanai S., Liu J., Patapoff T.W., Shire S.J. Carboxylate-dependent gelation of a monoclonal antibody. Pharm. Res. 2009, 26:2478-2485.
44. Gomez G., Pikal M.J., Rodriguez-Hornedo N. Effect of initial buffer composition on pH changes during far-from-equilibrium freezing of sodium phosphate buffer solutions. Pharm. Res. 2001, 18:90-97.
45. Pikal-Cleland K.A., Cleland J.L., Anchordoquy T.J., Carpenter J.F. Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems. J. Pharm. Sci. 2002, 91:1969-1979.
46. Pikal-Cleland K.A., Rodriguez-Hornedo N., Amidon G.L., Carpenter J.F. Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Arch. Biochem. Biophys. 2000, 384:398-406.
47. Kolhe P., Amend E., Singh S.K. Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation. Biotechnol. Prog. 2010, 26:727-733.
48. Sarciaux J.M., Mansour S., Hageman M.J., Nail S.L. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying. J. Pharm. Sci. 1999, 88:1354-1361.
49. Sundaramurthi P., Suryanarayanan R. Thermophysical properties of carboxylic and amino acid buffers at subzero temperatures: relevance to frozen state stabilization. J. Phys. Chem. B 2011, 115:7154-7164.
50. Sundaramurthi P., Suryanarayanan R. Predicting the crystallization propensity of carboxylic acid buffers in frozen systems-relevance to freeze-drying. J. Pharm. Sci. 2011, 100:1288-1293.
51. Sundaramurthi P., Suryanarayanan R. The effect of crystallizing and non-crystallizing cosolutes on succinate buffer crystallization and the consequent pH shift in frozen solutions. Pharm. Res. 2011, 28:374-385.
52. Varshney D.B., Kumar S., Shalaev E.Y., Sundaramurthi P., Kang S.W., Gatlin L.A., Suryanarayanan R. Glycine crystallization in frozen and freeze-dried systems: effect of pH and buffer concentration. Pharm. Res. 2007, 24:593-604.
53. Song Y., Schowen R.L., Borchardt R.T., Topp E.M. Formaldehyde production by Tris buffer in peptide formulations at elevated temperature. J. Pharm. Sci. 2001, 90:1198-1203.
54. Valliere-Douglass J.F., Connell-Crowley L., Jensen R., Schnier P.D., Trilisky E., Leith M., Follstad B.D., Kerr J., Lewis N., Vunnum S., Treuheit M.J., Balland A., Wallace A. Photochemical degradation of citrate buffers leads to covalent acetonation of recombinant protein therapeutics. Protein Sci. 2010, 19:2152-2163.
55. Arakawa T., Ejima D., Tsumoto K., Obeyama N., Tanaka Y., Kita Y., Timasheff S.N. Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects. Biophys. Chem. 2007, 127:1-8.
56. Arakawa T., Tsumoto K., Kita Y., Chang B., Ejima D. Biotechnology applications of amino acids in protein purification and formulations. Amino Acids 2007, 33:587-605.
57. Chen B., Bautista R., Yu K., Zapata G.A., Mulkerrin M.G., Chamow S.M. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm. Res. 2003, 20:1952-1960.
58. Tian F., Middaugh C.R., Offerdahl T., Munson E., Sane S., Rytting J.H. Spectroscopic evaluation of the stabilization of humanized monoclonal antibodies in amino acid formulations. Int. J. Pharm. 2007, 335:20-31.
59. Wade A.M., Tucker H.N. Antioxidant characteristics of l-histidine. J. Nutr. Biochem. 1998, 9:308-315.
60. Yates Z., Gunasekaran K., Zhou H., Hu Z., Liu Z., Ketchem R.R., Yan B. Histidine residue mediates radical-induced hinge cleavage of human IgG1. J. Biol. Chem. 2010, 285:18662-18671.
61. Lange C., Rudolph R. Suppression of protein aggregation by l-arginine. Curr. Pharm. Biotechnol. 2009, 10:408-414.
62. Nakakido M., Kudou M., Arakawa T., Tsumoto K. To be excluded or to bind, that is the question: arginine effects on proteins. Curr. Pharm. Biotechnol. 2009, 10:415-420.
63. Shukla D., Trout B.L. Interaction of arginine with proteins and the mechanism by which it inhibits aggregation. J. Phys. Chem. B 2010, 114:13426-13438.
64. Pyne A., Suryanarayanan R. Phase transitions of glycine in frozen aqueous solutions and during freeze-drying. Pharm. Res. 2001, 18:1448-1454.
65. Lam X.M., Yang J.Y., Cleland J.L. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J. Pharm. Sci. 1997, 86:1250-1255.
66. Maeder W., Lieby P., Sebald A., Spycher M., Pedrussio R., Bolli R. Local tolerance and stability up to 24months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals 2011, 39:43-49.
67. Kadoya S., Fujii K., Izutsu K., Yonemochi E., Terada K., Yomota C., Kawanishi T. Freeze-drying of proteins with glass-forming oligosaccharide-derived sugar alcohols. Int. J. Pharm. 2010, 389:107-113.
68. Golovanov A.P., Hautbergue G.M., Wilson S.A., Lian L.Y. A simple method for improving protein solubility and long-term stability. J. Am. Chem. Soc. 2004, 126:8933-8939.
69. Kumar R. Role of naturally occurring osmolytes in protein folding and stability. Arch. Biochem. Biophys. 2009, 491:1-6.
70. Arakawa T., Timasheff S.N. The stabilization of proteins by osmolytes. Biophys. J. 1985, 47:411-414.
71. Auton M., Bolen D.W., Rosgen J. Structural thermodynamics of protein preferential solvation: osmolyte solvation of proteins, aminoacids, and peptides. Proteins 2008, 73:802-813.
72. Bolen D.W. Effects of naturally occurring osmolytes on protein stability and solubility: issues important in protein crystallization. Methods 2004, 34:312-322.
73. Timasheff S.N. Protein hydration, thermodynamic binding, and preferential hydration. Biochemistry 2002, 41:13473-13482.
74. Hu C.Y., Pettitt B.M., Roesgen J. Osmolyte solutions and protein folding. F1000 Biol. Rep. 2009, 1:41.
75. Singh L.R., Dar T.A., Ahmad F. Living with urea stress. J. Biosci. 2009, 34:321-331.
76. Vagenende V., Yap M.G., Trout B.L. Mechanisms of protein stabilization and prevention of protein aggregation by glycerol. Biochemistry 2009, 48:11084-11096.
77. Singh L.R., Poddar N.K., Dar T.A., Kumar R., Ahmad F. Protein and DNA destabilization by osmolytes: the other side of the coin. Life Sci. 2011, 88:117-125.
78. Kaushik J.K., Bhat R. Why is trehalose an exceptional protein stabilizer? An analysis of the thermal stability of proteins in the presence of the compatible osmolyte trehalose. J. Biol. Chem. 2003, 278:26458-26465.
79. Kendrick B.S., Chang B.S., Arakawa T., Peterson B., Randolph T.W., Manning M.C., Carpenter J.F. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11917-11922.
80. Kim Y.S., Jones L.S., Dong A., Kendrick B.S., Chang B.S., Manning M.C., Randolph T.W., Carpenter J.F. Effects of sucrose on conformational equilibria and fluctuations within the native-state ensemble of proteins. Protein Sci. 2003, 12:1252-1261.
81. Ohtake S., Wang Y.J. Trehalose: current use and future applications. J. Pharm. Sci. 2011, 100:2020-2053.
82. Bhatnagar B.S., Bogner R.H., Pikal M.J. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm. Dev. Technol. 2007, 12:505-523.
83. Chang L.L., Pikal M.J. Mechanisms of protein stabilization in the solid state. J. Pharm. Sci. 2009, 98:2886-2908.
84. Chang L.L., Shepherd D., Sun J., Ouellette D., Grant K.L., Tang X.C., Pikal M.J. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?. J. Pharm. Sci. 2005, 94:1427-1444.
85. Chang L.L., Shepherd D., Sun J., Tang X.C., Pikal M.J. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: implications for the mechanism of protein stabilization in the solid state. J. Pharm. Sci. 2005, 94:1445-1455.
86. Cleland J.L., Lam X., Kendrick B., Yang J., Yang T.H., Overcashier D., Brooks D., Hsu C., Carpenter J.F. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J. Pharm. Sci. 2001, 90:310-321.
87. He F., Woods C.E., Litowski J.R., Roschen L.A., Gadgil H.S., Razinkov V.I., Kerwin B.A. Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions. Pharm. Res. 2011, 28:1552-1560.
88. Piedmonte D.M., Summers C., McAuley A., Karamujic L., Ratnaswamy G. Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharm. Res. 2007, 24:136-146.
89. Meyer J.D., Nayar R., Manning M.C. Impact of bulking agents on the stability of a lyophilized monoclonal antibody. Eur. J. Pharm. Sci. 2009, 38:29-38.
90. Johnson R.E., Kirchhoff C.F., Gaud H.T. Mannitol-sucrose mixtures-versatile formulations for protein lyophilization. J. Pharm. Sci. 2002, 91:914-922.
91. Ibrahim B.M., Jun S.W., Lee M.Y., Kang S.H., Yeo Y. Development of inhalable dry powder formulation of basic fibroblast growth factor. Int. J. Pharm. 2010, 385:66-72.
92. Bosquillon C., Lombry C., Preat V., Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 2001, 70:329-339.
93. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6:67-74.
94. Serno T., Carpenter J.F., Randolph T.W., Winter G. Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta-cyclodextrin. J. Pharm. Sci. 2010, 99:1193-1206.
95. Samra H.S., He F., Bhambhani A., Pipkin J.D., Zimmerer R., Joshi S.B., Middaugh C.R. The effects of substituted cyclodextrins on the colloidal and conformational stability of selected proteins. J. Pharm. Sci. 2010, 99:2800-2818.
96. Brewster M.E., Hora M.S., Simpkins J.W., Bodor N. Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res. 1991, 8:792-795.
97. Xu H., Templeton A.C., Reed R.A. Quantification of 5-HMF and dextrose in commercial aqueous dextrose solutions. J. Pharm. Biomed. Anal. 2003, 32:451-459.
98. Banks D.D., Hambly D.M., Scavezze J.L., Siska C.C., Stackhouse N.L., Gadgil H.S. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J. Pharm. Sci. 2009, 98:4501-4510.
99. Smales C.M., Pepper D.S., James D.C. Protein modification during anti-viral heat-treatment bioprocessing of factor VIII concentrates, factor IX concentrates, and model proteins in the presence of sucrose. Biotechnol. Bioeng. 2002, 77:37-48.
100. Li S., Patapoff T.W., Overcashier D., Hsu C., Nguyen T.H., Borchardt R.T. Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state. J. Pharm. Sci. 1996, 85:873-877.
101. Chuang V.T., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 2002, 19:569-577.
102. Costantino H.R., Langer R., Klibanov A.M. Aggregation of a lyophilized pharmaceutical protein, recombinant human albumin: effect of moisture and stabilization by excipients. Biotechnology (N Y) 1995, 13:493-496.
103. Hawe A., Friess W. Formulation development for hydrophobic therapeutic proteins. Pharm. Dev. Technol. 2007, 12:223-237.
104. Oliva A., Santovena A., Llabres M., Farina J.B. Stability study of human serum albumin pharmaceutical preparations. J. Pharm. Pharmacol. 1999, 51:385-392.
105. Thyagarajapuram N., Olsen D., Middaugh C.R. The structure, stability, and complex behavior of recombinant human gelatins. J. Pharm. Sci. 2007, 96:3363-3378.
106. Yoshioka S., Aso Y., Kojima S. Dependence of the molecular mobility and protein stability of freeze-dried gamma-globulin formulations on the molecular weight of dextran. Pharm. Res. 1997, 14:736-741.
107. Garzon-Rodriguez W., Koval R.L., Chongprasert S., Krishnan S., Randolph T.W., Warne N.W., Carpenter J.F. Optimizing storage stability of lyophilized recombinant human interleukin-11 with disaccharide/hydroxyethyl starch mixtures. J. Pharm. Sci. 2004, 93:684-696.
108. Yoshioka S., Aso Y., Nakai Y., Kojima S. Effect of high molecular mobility of poly(vinyl alcohol) on protein stability of lyophilized gamma-globulin formulations. J. Pharm. Sci. 1998, 87:147-151.
109. Gombotz W.R., Pankey S.C., Phan D., Drager R., Donaldson K., Antonsen K.P., Hoffman A.S., Raff H.V. The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone). Pharm. Res. 1994, 11:624-632.
110. Izutsu K., Kojima S. Freeze-concentration separates proteins and polymer excipients into different amorphous phases. Pharm. Res. 2000, 17:1316-1322.
111. Pisal D.S., Kosloski M.P., Balu-Iyer S.V. Delivery of therapeutic proteins. J. Pharm. Sci. 2010, 99:2557-2575.
112. Tiwari A.K., Gajbhiye V., Sharma R., Jain N.K. Carrier mediated protein and peptide stabilization. Drug Deliv. 2010, 17:605-616.
113. Guo J.-H., Skinner G.W., Harcum W.W., Barnum P.E. Pharmaceutical applications of naturally-occurring water-soluble polymers. Pharm. Sci. Technol. Today 1998, 1.
114. Tsai P.K., Volkin D.B., Dabora J.M., Thompson K.C., Bruner M.W., Gress J.O., Matuszewska B., Keogan M., Bondi J.V., Middaugh C.R. Formulation design of acidic fibroblast growth factor. Pharm. Res. 1993, 10:649-659.
115. Volkin D.B., Middaugh C.R. The characterization, stabilization, and formulation of acidic fibroblast growth factor. Pharm. Biotechnol. 1996, 9:181-217.
116. Zhang Y., Cremer P.S. Chemistry of Hofmeister anions and osmolytes. Annu. Rev. Phys. Chem. 2010, 61:63-83.
117. Zhang Y., Cremer P.S. Interactions between macromolecules and ions: the Hofmeister series. Curr. Opin. Chem. Biol. 2006, 10:658-663.
118. Gokarn Y.R., Fesinmeyer R.M., Saluja A., Razinkov V., Chase S.F., Laue T.M., Brems D.N. Effective charge measurements reveal selective and preferential accumulation of anions, but not cations, at the protein surface in dilute salt solutions. Protein Sci. 2011, 20:580-587.
119. Fesinmeyer R.M., Hogan S., Saluja A., Brych S.R., Kras E., Narhi L.O., Brems D.N., Gokarn Y.R. Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm. Res. 2009, 26:903-913.
120. Saluja A., Crampton S., Kras E., Fesinmeyer R.M., Remmele R.L., Narhi L.O., Brems D.N., Gokarn Y.R. Anion binding mediated precipitation of a peptibody. Pharm. Res. 2009, 26:152-160.
121. Liu J., Nguyen M.D., Andya J.D., Shire S.J. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J. Pharm. Sci. 2005, 94:1928-1940.
122. Kamerzell T.J., Kanai S., Liu J., Shire S.J., Wang Y.J. Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties. J. Phys. Chem. B 2009, 113:6109-6118.
123. Nesarikar V.V., Nassar M.N. Effect of cations and anions on glass transition temperatures in excipient solutions. Pharm. Dev. Technol. 2007, 12:259-264.
124. Mollmann S.H., Elofsson U., Bukrinsky J.T., Frokjaer S. Displacement of adsorbed insulin by Tween 80 monitored using total internal reflection fluorescence and ellipsometry. Pharm. Res. 2005, 22:1931-1941.
125. Deechongkit S., Wen J., Narhi L.O., Jiang Y., Park S.S., Kim J., Kerwin B.A. Physical and biophysical effects of polysorbate 20 and 80 on darbepoetin alfa. J. Pharm. Sci. 2009, 98:3200-3217.
126. Randolph T.W., Jones L.S. Surfactant-protein interactions. Pharm. Biotechnol. 2002, 13:159-175.
127. Mahler H.C., Senner F., Maeder K., Mueller R. Surface activity of a monoclonal antibody. J. Pharm. Sci. 2009, 98:4525-4533.
128. Kerwin B.A. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J. Pharm. Sci. 2008, 97:2924-2935.
129. Bam N.B., Cleland J.L., Yang J., Manning M.C., Carpenter J.F., Kelley R.F., Randolph T.W. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J. Pharm. Sci. 1998, 87:1554-1559.
130. Kreilgaard L., Jones L.S., Randolph T.W., Frokjaer S., Flink J.M., Manning M.C., Carpenter J.F. Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J. Pharm. Sci. 1998, 87:1597-1603.
131. Wang W., Wang Y.J., Wang D.Q. Dual effects of Tween 80 on protein stability. Int. J. Pharm. 2008, 347:31-38.
132. Chang B.S., Kendrick B.S., Carpenter J.F. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J. Pharm. Sci. 1996, 85:1325-1330.
133. Webb S.D., Cleland J.L., Carpenter J.F., Randolph T.W. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J. Pharm. Sci. 2002, 91:543-558.
134. Ha E., Wang W., Wang Y.J. Peroxide formation in polysorbate 80 and protein stability. J. Pharm. Sci. 2002, 91:2252-2264.
135. Mahler H.C., Printz M., Kopf R., Schuller R., Muller R. Behaviour of polysorbate 20 during dialysis, concentration and filtration using membrane separation techniques. J. Pharm. Sci. 2008, 97:764-774.
136. Hovorka S., Schoneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J. Pharm. Sci. 2001, 90:253-269.
137. Towne V., Oswald C.B., Mogg R., Antonello J., Will M., Gimenez J., Washabaugh M., Sitrin R., Zhao Q. Measurement and decomposition kinetics of residual hydrogen peroxide in the presence of commonly used excipients and preservatives. J. Pharm. Sci. 2009, 98:3987-3996.
138. Buettner G.R., Jurkiewicz B.A. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat. Res. 1996, 145:532-541.
139. Zhou S., Zhang B., Sturm E., Teagarden D.L., Schoneich C., Kolhe P., Lewis L.M., Muralidhara B.K., Singh S.K. Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody. J. Pharm. Sci. 2010, 99:4239-4250.
140. Evans R.K., Nawrocki D.K., Isopi L.A., Williams D.M., Casimiro D.R., Chin S., Chen M., Zhu D.M., Shiver J.W., Volkin D.B. Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci. 2004, 93:2458-2475.
141. Evans R.K., Xu Z., Bohannon K.E., Wang B., Bruner M.W., Volkin D.B. Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies. J. Pharm. Sci. 2000, 89:76-87.
142. Evans R.K., Zhu D.M., Casimiro D.R., Nawrocki D.K., Mach H., Troutman R.D., Tang A., Wu S., Chin S., Ahn C., Isopi L.A., Williams D.M., Xu Z., Shiver J.W., Volkin D.B. Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines. J. Pharm. Sci. 2004, 93:1924-1939.
143. Zeng Y., Ramsey J.D., King R., Leviten M., McGuire R., Volkin D.B., Joshi S.B., Middaugh C.R. Identifying stabilizers of plasmid DNA for pharmaceutical use. J. Pharm. Sci. 2011, 100:904-914.
144. Qi P., Volkin D.B., Zhao H., Nedved M.L., Hughes R., Bass R., Yi S.C., Panek M.E., Wang D., Dalmonte P., Bond M.D. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. J. Pharm. Sci. 2009, 98:3117-3130.
145. Derrick T.S., Kashi R.S., Durrani M., Jhingan A., Middaugh C.R. Effect of metal cations on the conformation and inactivation of recombinant human factor VIII. J. Pharm. Sci. 2004, 93:2549-2557.
146. Liu W., Swift R., Torraca G., Nashed-Samuel Y., Wen Z.Q., Jiang Y., Vance A., Mire-Sluis A., Freund E., Davis J., Narhi L. Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes. PDA J. Pharm. Sci. Technol. 2010, 64:11-19.
147. Jiang Y., Nashed-Samuel Y., Li C., Liu W., Pollastrini J., Mallard D., Wen Z.Q., Fujimori K., Pallitto M., Donahue L., Chu G., Torraca G., Vance A., Mire-Sluis T., Freund E., Davis J., Narhi L. Tungsten-induced protein aggregation: solution behavior. J. Pharm. Sci. 2009, 98:4695-4710.
148. Meyer B.K., Ni A., Hu B., Shi L. Antimicrobial preservative use in parenteral products: past and present. J. Pharm. Sci. 2007, 96:3155-3167.
149. Gupta S., Kaisheva E. Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS PharmSci 2003, 5:E8.
150. Maa Y.-F., Hsu C.C. Aggregation of recombinant human growth hormone induced by phenolic compounds. Int. J. Pharm. 1996, 140:155-168.
151. Zhang Y., Roy S., Jones L.S., Krishnan S., Kerwin B.A., Chang B.S., Manning M.C., Randolph T.W., Carpenter J.F. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. J. Pharm. Sci. 2004, 93:3076-3089.
152. Tobler S.A., Holmes B.W., Cromwell M.E., Fernandez E.J. Benzyl alcohol-induced destabilization of interferon-gamma: a study by hydrogen-deuterium isotope exchange. J. Pharm. Sci. 2004, 93:1605-1617.
153. Thirumangalathu R., Krishnan S., Brems D.N., Randolph T.W., Carpenter J.F. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J. Pharm. Sci. 2006, 95:1480-1497.
154. Lam X.M., Patapoff T.W., Nguyen T.H. The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm. Res. 1997, 14:725-729.
155. Fransson J., Hallen D., Florin-Robertsson E. Solvent effects on the solubility and physical stability of human insulin-like growth factor I. Pharm. Res. 1997, 14:606-612.
156. Roy S., Katayama D., Dong A., Kerwin B.A., Randolph T.W., Carpenter J.F. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. Biochemistry 2006, 45:3898-3911.
157. Chen B., Costantino H.R., Liu J., Hsu C.C., Shire S.J. Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease I in the aqueous and lyophilized states. J. Pharm. Sci. 1999, 88:477-482.
158. Shire S.J. Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme, (dornase alpha)]. Pharm. Biotechnol. 1996, 9:393-426.
159. Volkin D.B., Burke C.J., Marfia K.E., Oswald C.B., Wolanski B., Middaugh C.R. Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine. J. Pharm. Sci. 1997, 86:666-673.
160. Dorval B.L., Chow M., Klibanov A.M. Lysine and other diamines dramatically stabilize poliovirus against thermoinactivation. Biotechnol. Bioeng. 1990, 35:1051-1054.
161. Brange J., Langkjoer L. Insulin structure and stability. Pharm. Biotechnol. 1993, 5:315-350.
162. Huus K., Havelund S., Olsen H.B., van de Weert M., Frokjaer S. Chemical and thermal stability of insulin: effects of zinc and ligand binding to the insulin zinc-hexamer. Pharm. Res. 2006, 23:2611-2620.
163. Avanti C., Amorij J.P., Setyaningsih D., Hawe A., Jiskoot W., Visser J., Kedrov A., Driessen A.J., Hinrichs W.L., Frijlink H.W. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. AAPS J. 2011, 13:284-290.
164. Volkin D.B., Tsai P.K., Dabora J.M., Gress J.O., Burke C.J., Linhardt R.J., Middaugh C.R. Physical stabilization of acidic fibroblast growth factor by polyanions. Arch. Biochem. Biophys. 1993, 300:30-41.
165. Nguyen T.H., Ward C. Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen activator. Pharm. Biotechnol. 1993, 5:91-134.
166. Fox S., Farr-Jones S., Sopchak L., Boggs A., Nicely H.W., Khoury R., Biros M. High-throughput screening: update on practices and success. J. Biomol. Screen. 2006, 11:864-869.
167. Macarron R., Banks M.N., Bojanic D., Burns D.J., Cirovic D.A., Garyantes T., Green D.V., Hertzberg R.P., Janzen W.P., Paslay J.W., Schopfer U., Sittampalam G.S. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 2011, 10:188-195.
168. Macarron R., Hertzberg R.P. Design and implementation of high throughput screening assays. Mol. Biotechnol. 2011, 47:270-285.
169. Mayr L.M., Bojanic D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 2009, 9:580-588.
170. Laughrey Z.R., Kiehna S.E., Riemen A.J., Waters M.L. Carbohydrate-pi interactions: what are they worth?. J. Am. Chem. Soc. 2008, 130:14625-14633.
171. Wensel D.L., Kelley B.D., Coffman J.L. High-throughput screening of chromatographic separations: III. Monoclonal antibodies on ceramic hydroxyapatite. Biotechnol. Bioeng. 2008, 100:839-854.
172. Kramarczyk J.F., Kelley B.D., Coffman J.L. High-throughput screening of chromatographic separations: II. Hydrophobic interaction. Biotechnol. Bioeng. 2008, 100:707-720.
173. Kelley B.D., Switzer M., Bastek P., Kramarczyk J.F., Molnar K., Yu T., Coffman J. High-throughput screening of chromatographic separations: IV. Ion-exchange. Biotechnol. Bioeng. 2008, 100:950-963.
174. Coffman J.L., Kramarczyk J.F., Kelley B.D. High-throughput screening of chromatographic separations: I. Method development and column modeling. Biotechnol. Bioeng. 2008, 100:605-618.
175. He F., Woods C.E., Trilisky E., Bower K.M., Litowski J.R., Kerwin B.A., Becker G.W., Narhi L.O., Razinkov V.I. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J. Pharm. Sci. 2011, 100:1330-1340.
176. He F., Hogan S., Latypov R.F., Narhi L.O., Razinkov V.I. High throughput thermostability screening of monoclonal antibody formulations. J. Pharm. Sci. 2010, 99:1707-1720.
177. He F., Becker G.W., Litowski J.R., Narhi L.O., Brems D.N., Razinkov V.I. High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal. Biochem. 2010, 399:141-143.
178. Esfandiary R., Yee L., Ohtake S., Martin R.A., Truong-Le V.L., Lechuga-Ballesteros D., Moore D.S., Joshi S.B., Middaugh C.R. Biophysical characterization of rotavirus serotypes G1, G3 and G4. Hum. Vaccin. 2010, 6:390-398.
179. Peek L.J., Brandau D.T., Jones L.S., Joshi S.B., Middaugh C.R. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 2006, 24:5839-5851.
180. Zeng Y., Fan H., Chiueh G., Pham B., Martin R., Lechuga-Ballesteros D., Truong V.L., Joshi S.B., Middaugh C.R. Towards development of stable formulations of a live attenuated bacterial vaccine: a preformulation study facilitated by a biophysical approach. Hum. Vaccin. 2009, 5:322-331.
181. Zheng K., Middaugh C.R., Siahaan T.J. Evaluation of the physical stability of the EC5 domain of E-cadherin: effects of pH, temperature, ionic strength, and disulfide bonds. J. Pharm. Sci. 2009, 98:63-73.
182. Zheng K., Laurence J.S., Kuczera K., Verkhivker G., Middaugh C.R., Siahaan T.J. Characterization of multiple stable conformers of the EC5 domain of E-cadherin and the interaction of EC5 with E-cadherin peptides. Chem. Biol. Drug Des. 2009, 73:584-598.
183. Salnikova M.S., Middaugh C.R., Rytting J.H. Stability of lyophilized human growth hormone. Int. J. Pharm. 2008, 358:108-113.
184. Nonoyama A., Laurence J.S., Garriques L., Qi H., Le T., Middaugh C.R. A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams. J. Pharm. Sci. 2008, 97:2552-2567.
185. Markham A.P., Birket S.E., Picking W.D., Picking W.L., Middaugh C.R. pH sensitivity of type III secretion system tip proteins. Proteins 2008, 71:1830-1842.
186. Thyagarajapuram N., Olsen D., Middaugh C.R. Stabilization of proteins by recombinant human gelatins. J. Pharm. Sci. 2007, 96:3304-3315.
187. Fan H., Vitharana S.N., Chen T., O'Keefe D., Middaugh C.R. Effects of pH and polyanions on the thermal stability of fibroblast growth factor 20. Mol. Pharm. 2007, 4:232-240.
188. Fan H., Li H., Zhang M., Middaugh C.R. Effects of solutes on empirical phase diagrams of human fibroblast growth factor 1. J. Pharm. Sci. 2007, 96:1490-1503.
189. Derrick T., Grillo A.O., Vitharana S.N., Jones L., Rexroad J., Shah A., Perkins M., Spitznagel T.M., Middaugh C.R. Effect of polyanions on the structure and stability of repifermin (keratinocyte growth factor-2). J. Pharm. Sci. 2007, 96:761-776.
190. Ramsey J.D., Gill M.L., Kamerzell T.J., Price E.S., Joshi S.B., Bishop S.M., Oliver C.N., Middaugh C.R. Using empirical phase diagrams to understand the role of intramolecular dynamics in immunoglobulin G stability. J. Pharm. Sci. 2009, 98:2432-2447.
191. Wuchner K., Buchler J., Spycher R., Dalmonte P., Volkin D.B. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J. Pharm. Sci. 2010, 99:3343-3361.
192. Li Y., Mach H., Blue J.T. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. J. Pharm. Sci. 2011, 100:2120-2135.
193. Kissmann J., Joshi S.B., Haynes J.R., Dokken L., Richardson C., Middaugh C.R. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers. J. Pharm. Sci. 2011, 100:634-645.
194. Volkin D.B., Middaugh C.R. Vaccines as physically and chemically well-defined pharmaceutical dosage forms. Expert Rev. Vaccines 2010, 9:689-691.
195. He F., Joshi S.B., Moore D.S., Shinogle H.E., Ohtake S., Lechuga-Ballesteros D., Martin R.A., Truong-Le V.L., Middaugh C.R. Using spectroscopic and microscopic methods to probe the structural stability of human adenovirus type 4. Hum. Vaccin. 2010, 6.
196. He F., Joshi S.B., Bosman F., Verhaeghe M., Middaugh C.R. Structural stability of hepatitis C virus envelope glycoprotein E1: effect of pH and dissociative detergents. J. Pharm. Sci. 2009, 98:3340-3357.
197. Esfandiary R., Kickhoefer V.A., Rome L.H., Joshi S.B., Middaugh C.R. Structural stability of vault particles. J. Pharm. Sci. 2009, 98:1376-1386.
198. Kissmann J., Ausar S.F., Rudolph A., Braun C., Cape S.P., Sievers R.E., Federspiel M.J., Joshi S.B., Middaugh C.R. Stabilization of measles virus for vaccine formulation. Hum. Vaccin. 2008, 4:350-359.
199. Kissmann J., Ausar S.F., Foubert T.R., Brock J., Switzer M.H., Detzi E.J., Vedvick T.S., Middaugh C.R. Physical stabilization of Norwalk virus-like particles. J. Pharm. Sci. 2008, 97:4208-4218.
200. Ausar S.F., Espina M., Brock J., Thyagarayapuran N., Repetto R., Khandke L., Middaugh C.R. High-throughput screening of stabilizers for respiratory syncytial virus: identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum. Vaccin. 2007, 3:94-103.
201. Rexroad J., Martin T.T., McNeilly D., Godwin S., Middaugh C.R. Thermal stability of adenovirus type 2 as a function of pH. J. Pharm. Sci. 2006, 95:1469-1479.
202. Rexroad J., Evans R.K., Middaugh C.R. Effect of pH and ionic strength on the physical stability of adenovirus type 5. J. Pharm. Sci. 2006, 95:237-247.
203. Barth A., Zscherp C. What vibrations tell us about proteins. Q. Rev. Biophys. 2002, 35:369-430.
204. Gendrin C., Roggo Y., Collet C. Pharmaceutical applications of vibrational chemical imaging and chemometrics: a review. J. Pharm. Biomed. Anal. 2008, 48:533-553.
205. Middaugh C.R., Mach H., Ryan J.A., Sanyal G., Volkin D.B. Infrared spectroscopy. Methods Mol. Biol. 1995, 40:137-156.
206. Abe Y., Krimm S. Normal vibrations of polyglycine II. Biopolymers 1972, 11:1841-1853.
207. Hamm P., Lim M., DeGrado W.F., Hochstrasser R.M. The two-dimensional IR nonlinear spectroscopy of a cyclic penta-peptide in relation to its three-dimensional structure. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2036-2041.
208. Krimm S., Abe Y. Intermolecular interaction effects in the amide I vibrations of polypeptides. Proc. Natl. Acad. Sci. U. S. A. 1972, 69:2788-2792.
209. Krimm S., Bandekar J. Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. Adv. Protein Chem. 1986, 38:181-364.
210. Torii H., Tatsumi T., Kanazawa T., Tasumi M. Effects of intermolecular hydrogen-bonding interactions on the amide I mode of N-methylacetamide: matrix-isolation infrared studies and ab initio molecular orbital calculations. J. Phys. Chem. B 1998, 102:309-314.
211. Torii H., Tatsumi T., Tatsumi M. Effects of hydration on the structure, vibration wavenumbers, vibrational force field and resonance Raman intensities of N-methylacetamide. J. Raman Spectrosc. 1998, 29:537-546.
212. Jackson M., Mantsch H.H. Protein secondary structure from FT-IR spectroscopy: correlation with dihedral angles from three dimensional Ramachandran plots. Can. J. Chem. 1991, 69:1639-1642.
213. Chirgadze Y.N., Nevskaya N.A. Infrared spectra and resonance interaction of amide-I vibration of the parallel-chain pleated sheets. Biopolymers 1976, 15:627-636.
214. Chirgadze Y.N., Nevskaya N.A. Infrared spectra and resonance interaction of amide-I vibration of the antiparallel-chain pleated sheet. Biopolymers 1976, 15:607-625.
215. Nevskaya N.A., Chirgadze Y.N. Infrared spectra and resonance interactions of amide-I and II vibration of alpha-helix. Biopolymers 1976, 15:637-648.
216. Goormaghtigh E., Ruysschaert J.M., Raussens V. Evaluation of the information content in infrared spectra for protein secondary structure determination. Biophys. J. 2006, 90:2946-2957.
217. Thomas G.J. Raman spectroscopy of protein and nucleic acid assemblies. Annu. Rev. Biophys. Biomol. Struct. 1999, 28:1-27.
218. Wen Z.Q. Raman spectroscopy of protein pharmaceuticals. J. Pharm. Sci. 2007, 96:2861-2878.
219. Sane S.U., Cramer S.M., Przybycien T.M. A holistic approach to protein secondary structure characterization using amide I band Raman spectroscopy. Anal. Biochem. 1999, 269:255-272.
220. Stiles P.L., Dieringer J.A., Shah N.C., Van Duyne R.P. Surface-enhanced Raman spectroscopy. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 2008, 1:601-626.
221. Fang Y., Seong N.H., Dlott D.D. Measurement of the distribution of site enhancements in surface-enhanced Raman scattering. Science 2008, 321:388-392.
222. Habuchi S., Cotlet M., Gronheid R., Dirix G., Michiels J., Vanderleyden J., De Schryver F.C., Hofkens J. Single-molecule surface enhanced resonance Raman spectroscopy of the enhanced green fluorescent protein. J. Am. Chem. Soc. 2003, 125:8446-8447.
223. Qian X.M., Nie S.M. Single-molecule and single-nanoparticle SERS: from fundamental mechanisms to biomedical applications. Chem. Soc. Rev. 2008, 37:912-920.
224. Lombardi J.R., Birke R.L. A unified view of surface-enhanced Raman scattering. Acc. Chem. Res. 2009, 42:734-742.
225. Keiderling T.A. Protein and peptide secondary structure and conformational determination with vibrational circular dichroism. Curr. Opin. Chem. Biol. 2002, 6:682-688.
226. Stephens P.J. Vibrational circular dichroism. Annu. Rev. Phys. Chem. 1985, 36:213-241.
227. Barron L.D., Buckingham A.D. Vibrational optical activity. Chem. Phys. Lett. 2010, 492:199-213.
228. Nafie L.A., Dukor R.K. Applications of vibrational optical activity in the pharmaceutical industry. The Handbook of Vibrational Spectroscopy 2007, John Wiley and Sons. D. Pivonka, J. Chalmers, P. Griffiths (Eds.).
229. M.D. Fayer, Dynamics of water interacting with interfaces, molecules, and ions, Acc. Chem. Res. (in press), doi:. doi:10.1021/ar2000088.
230. Bagchi S., Thorpe D.G., Thorpe I.F., Voth G.A., Fayer M.D. Conformational switching between protein substates studied with 2D IR vibrational echo spectroscopy and molecular dynamics simulations. J. Phys. Chem. B 2010, 114:17187-17193.
231. Moilanen D.E., Wong D., Rosenfeld D.E., Fenn E.E., Fayer M.D. Ion-water hydrogen-bond switching observed with 2D IR vibrational echo chemical exchange spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:375-380.
232. Fayer M.D., Moilanen D.E., Wong D., Rosenfeld D.E., Fenn E.E., Park S. Water dynamics in salt solutions studied with ultrafast two-dimensional infrared (2D IR) vibrational echo spectroscopy. Acc. Chem. Res. 2009, 42:1210-1219.
233. Fayer M.D. Dynamics of liquids, molecules, and proteins measured with ultrafast 2D IR vibrational echo chemical exchange spectroscopy. Annu. Rev. Phys. Chem. 2009, 60:21-38.
234. Zheng J., Kwak K., Fayer M.D. Ultrafast 2D IR vibrational echo spectroscopy. Acc. Chem. Res. 2007, 40:75-83.
235. Ganim Z., Chung H.S., Smith A.W., Deflores L.P., Jones K.C., Tokmakoff A. Amide I two-dimensional infrared spectroscopy of proteins. Acc. Chem. Res. 2008, 41:432-441.
236. Chung H.S., Tokmakoff A. Visualization and characterization of the infrared active amide I vibrations of proteins. J. Phys. Chem. B 2006, 110:2888-2898.
237. Ghosh A., Tucker M.J., Hochstrasser R.M. Identification of arginine residues in peptides by 2D-IR echo spectroscopy. J. Phys. Chem. A 2011, 115:9731-9738.
238. Vorobyev D.Y., Kuo C.H., Chen J.X., Kuroda D.G., Scott J.N., Vanderkooi J.M., Hochstrasser R.M. Ultrafast vibrational spectroscopy of a degenerate mode of guanidinium chloride. J. Phys. Chem. B 2009, 113:15382-15391.
239. Kim Y.S., Liu L., Axelsen P.H., Hochstrasser R.M. 2D IR provides evidence for mobile water molecules in beta-amyloid fibrils. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17751-17756.
240. Hochstrasser R.M. Multidimensional ultrafast spectroscopy special feature: multidimensional ultrafast spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14189.
241. Woody R.W. Circular dichroism. Methods Enzymol. 1995, 246:34-71.
242. Sreerama N., Woody R.W. Computation and analysis of protein circular dichroism spectra. Methods Enzymol. 2004, 383:318-351.
243. Sreerama N., Woody R.W. On the analysis of membrane protein circular dichroism spectra. Protein Sci. 2004, 13:100-112.
244. Johnson C.W. Protein secondary structure and circular dichroism: a practical guide. Proteins: Struct. Funct. Genet. 1990, 7:205-214.
245. Kueltzo L.A., Middaugh C.R. Ultraviolet absorption spectroscopy. Methods for Structural Analysis of Protein Pharmaceuticals 2005, American Association of Pharmaceutical Scientists, Arlington, VA. W. Jiskoot, D.J. Crommelin (Eds.).
246. Mach H., Volkin D.B., Burke C.J., Middaugh C.R. Ultraviolet absorption spectroscopy. Methods Mol. Biol. 1995, 40:91-114.
247. Mach H., Middaugh C.R. Ultraviolet spectroscopy as a tool in therapeutic protein development. J. Pharm. Sci. 2011, 100:1214-1227.
248. Kueltzo L.A., Ersoy B., Ralston J.P., Middaugh C.R. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J. Pharm. Sci. 2003, 92:1805-1820.
249. Esfandiary R., Hunjan J.S., Lushington G.H., Joshi S.B., Middaugh C.R. Temperature dependent 2nd derivative absorbance spectroscopy of aromatic amino acids as a probe of protein dynamics. Protein Sci. 2009, 18:2603-2614.
250. Lucas L.H., Ersoy B.A., Kueltzo L.A., Joshi S.B., Brandau D.T., Thyagarajapuram N., Peek L.J., Middaugh C.R. Probing protein structure and dynamics by second-derivative ultraviolet absorption analysis of cation-{pi} interactions. Protein Sci. 2006, 15:2228-2243.
251. Lakowicz J.R. Principles of Fluorescence Spectroscopy 1999, Kluwer Academic/Plenum Publishers, New York. 2nd ed.
252. Klunk W.E., Pettegrew J.W., Abraham D.J. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 1989, 37:1273-1281.
253. LeVine H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999, 309:274-284.
254. Kamerzell T.J., Unruh J.R., Johnson C.K., Middaugh C.R. Conformational flexibility, hydration and state parameter fluctuations of fibroblast growth factor-10: effects of ligand binding. Biochemistry 2006, 45:15288-15300.
255. Peek L.J., Martin T.T., Elk Nation C., Pegram S.A., Middaugh C.R. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J. Pharm. Sci. 2007, 96:547-557.
256. Kremer F., Schonhals A. Broadband Dielectric Spectroscopy 2002, Springer-Verlag, Berlin Heidelberg.
257. Smith G., Duffy A.P., Shen J., Olliff C.J. Dielectric relaxation spectroscopy and some applications in the pharmaceutical sciences. J. Pharm. Sci. 1995, 84:1029-1044.
258. Kamerzell T.J., Ramsey J.D., Middaugh C.R. Immunoglobulin dynamics, conformational fluctuations, and nonlinear elasticity and their effects on stability. J. Phys. Chem. B 2008, 112:3240-3250.
259. Kharakoz D.P., Sarvazyan A.P. Hydrational and intrinsic compressibilities of globular proteins. Biopolymers 1993, 33:11-26.
260. Sarvazyan A.P. Ultrasonic velocimetry of biological compounds. Annu. Rev. Biophys. Biophys. Chem. 1991, 20:321-342.
261. Doan-Nguyen V., Loria J.P. The effects of cosolutes on protein dynamics: the reversal of denaturant-induced protein fluctuations by trimethylamine N-oxide. Protein Sci. 2007, 16:20-29.
262. Frank M.K., Clore G.M., Gronenborn A.M. Structural and dynamic characterization of the urea denatured state of the immunoglobulin binding domain of streptococcal protein G by multidimensional heteronuclear NMR spectroscopy. Protein Sci. 1995, 4:2605-2615.
263. Ishima R., Torchia D.A. Protein dynamics from NMR. Nat. Struct. Biol. 2000, 7:740-743.
264. Mittermaier A., Kay L.E. New tools provide new insights in NMR studies of protein dynamics. Science 2006, 312:224-228.
265. Skinner A.L., Laurence J.S. High-field solution NMR spectroscopy as a tool for assessing protein interactions with small molecule ligands. J. Pharm. Sci. 2008, 97:4670-4695.
266. Skinner A.L., Laurence J.S. Probing residue-specific interactions in the stabilization of proteins using high-resolution NMR: a study of disulfide bond compensation. J. Pharm. Sci. 2010, 99:2643-2654.
267. Knox D.G., Rosenberg A. Fluctuations of protein structure as expressed in the distribution of hydrogen exchange rate constants. Biopolymers 1980, 19:1049-1068.
268. Bai Y. Protein folding pathways studied by pulsed- and native-state hydrogen exchange. Chem. Rev. 2006, 106:1757-1768.
269. Bai Y., Sosnick T.R., Mayne L., Englander S.W. Protein folding intermediates: native-state hydrogen exchange. Science 1995, 269:192-197.
270. Englander S.W., Mayne L., Bai Y., Sosnick T.R. Hydrogen exchange: the modern legacy of Linderstrom-Lang. Protein Sci. 1997, 6:1101-1109.
271. Englander S.W., Sosnick T.R., Englander J.J., Mayne L. Mechanisms and uses of hydrogen exchange. Curr. Opin. Struct. Biol. 1996, 6:18-23.
272. Kamerzell T.J., Middaugh C.R. Two-dimensional correlation spectroscopy reveals coupled immunoglobulin regions of differential flexibility that influence stability. Biochemistry 2007, 46:9762-9773.
273. Lo M.C., Aulabaugh A., Jin G., Cowling R., Bard J., Malamas M., Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 2004, 332:153-159.
274. Markham A.P., Barrett B.S., Esfandiary R., Picking W.L., Picking W.D., Joshi S.B., Middaugh C.R. Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine. J. Pharm. Sci. 2010, 99:4497-4509.
275. Kamerzell T.J., Middaugh C.R. The complex inter-relationships between protein flexibility and stability. J. Pharm. Sci. 2008, 97:3494-3517.
276. Demchenko A.P. The red-edge effects: 30years of exploration. Luminescence 2002, 17:19-42.
277. Lakowicz J.R., Keating-Nakamoto S. Red-edge excitation of fluorescence and dynamic properties of proteins and membranes. Biochemistry 1984, 23:3013-3021.
278. Zhai Y., Okoro L., Cooper A., Winter R. Applications of pressure perturbation calorimetry in biophysical studies. Biophys. Chem. 2011, 156:13-23.
279. Sirotkin V.A., Winter R. Volume changes associated with guanidine hydrochloride, temperature, and ethanol induced unfolding of lysozyme. J. Phys. Chem. B 2010, 114:16881-16886.
280. Ravindra R., Winter R. Pressure perturbation calorimetry: a new technique provides surprising results on the effects of co-solvents on protein solvation and unfolding behaviour. Chemphyschem 2004, 5:566-571.
281. Sanchez-Ruiz J.M. Probing free-energy surfaces with differential scanning calorimetry. Annu. Rev. Phys. Chem. 2011, 62:231-255.
282. Cooper A., Johnson C.M. Differential scanning calorimetry. Methods in Molecular Biology: Microscopy, Optical Spectroscopy, and Macroscopic Techniques 1994, Humana Press, Totowa, NJ. C. Johnes, B. Mulloy, A.H. Thomas (Eds.).
283. Cooper A. Thermodynamic analysis of biomolecular interactions. Curr. Opin. Chem. Biol. 1999, 3:557-563.
284. Freire E., Mayorga O.L., Straume M. Isothermal titration calorimetry. Anal. Chem. 1990, 62:950A-959A.
285. Velazquez-Campoy A., Freire E. Isothermal titration calorimetry to determine association constants for high-affinity ligands. Nat. Protoc. 2006, 1:186-191.
286. Freire E., Schon A., Velazquez-Campoy A. Isothermal titration calorimetry: general formalism using binding polynomials. Methods Enzymol. 2009, 455:127-155.
287. Joshi S.B., Kamerzell T.J., McNown C., Middaugh C.R. The interaction of heparin/polyanions with bovine, porcine, and human growth hormone. J. Pharm. Sci. 2008, 97:1368-1385.
288. Kamerzell T.J., Joshi S.B., McClean D., Peplinskie L., Toney K., Papac D., Li M., Middaugh C.R. Parathyroid hormone is a heparin/polyanion binding protein: binding energetics and structure modification. Protein Sci. 2007, 16:1193-1203.
289. Harn N., Allan C., Oliver C., Middaugh C.R. Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability. J. Pharm. Sci. 2007, 96:532-546.
290. Kovrigin E.L., Potekhin S.A. Preferential solvation changes upon lysozyme heat denaturation in mixed solvents. Biochemistry 1997, 36:9195-9199.
291. Plaza del Pino I.M., Sanchez-Ruiz J.M. An osmolyte effect on the heat capacity change for protein folding. Biochemistry 1995, 34:8621-8630.
292. Schellman J.A. Macromolecular binding. Biopolymers 1975, 14:999-1018.
293. Schellman J.A. A simple model for solvation in mixed solvents. Applications to the stabilization and destabilization of macromolecular structures. Biophys. Chem. 1990, 37:121-140.
294. Kovrigin E.L., Potekhin S.A. Microcalorimetric study of the effect of dimethylsulfoxide on the heat denaturation of lysozyme. Biofizika 1996, 41:1201-1206.
295. Kovrigin E.L., Potekhin S.A. On the stabilizing action of protein denaturants: acetonitrile effect on stability of lysozyme in aqueous solutions. Biophys. Chem. 2000, 83:45-59.
296. Herberhold H., Royer C.A., Winter R. Effects of chaotropic and kosmotropic cosolvents on the pressure-induced unfolding and denaturation of proteins: an FT-IR study on staphylococcal nuclease. Biochemistry 2004, 43:3336-3345.
297. Zewail A.H. Four-dimensional electron microscopy. Science 2010, 328:187-193.
298. Lu P.J., Sims P.A., Oki H., Macarthur J.B., Weitz D.A. Target-locking acquisition with real-time confocal (TARC) microscopy. Opt. Express 2007, 15:8702-8712.
299. Semwogerere D., Weeks E.R. Confocal microscopy. Encyclopedia of Biomaterials and Biomedical Engineering 2005, Taylor and Francis.
300. Prasad V., Semwogerere D., Weeks E.R. Confocal microscopy of colloids. J. Phys. Condens. Matter 2007, 19:113102.
301. Hansma H.G. Varieties of imaging with scanning probe microscopes. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14678-14680.
302. Gross L., Mohn F., Moll N., Liljeroth P., Meyer G. The chemical structure of a molecule resolved by atomic force microscopy. Science 2009, 325:1110-1114.
303. Hinterdorfer P., Dufrene Y.F. Detection and localization of single molecular recognition events using atomic force microscopy. Nat. Methods 2006, 3:347-355.
304. Radmacher M., Tillmann R.W., Gaub H.E. Imaging viscoelasticity by force modulation with the atomic force microscope. Biophys. J. 1993, 64:735-742.
305. Puchner E.M., Gaub H.E. Force and function: probing proteins with AFM-based force spectroscopy. Curr. Opin. Struct. Biol. 2009, 19:605-614.
306. Garcia R., Magerle R., Perez R. Nanoscale compositional mapping with gentle forces. Nat. Mater. 2007, 6:405-411.
307. Sahin O., Magonov S., Su C., Quate C.F., Solgaard O. An atomic force microscope tip designed to measure time-varying nanomechanical forces. Nat. Nanotechnol. 2007, 2:507-514.
308. Dougan L., Genchev G.Z., Lu H., Fernandez J.M. Probing osmolyte participation in the unfolding transition state of a protein. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9759-9764.
309. Garcia-Manyes S., Dougan L., Fernandez J.M. Osmolyte-induced separation of the mechanical folding phases of ubiquitin. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10540-10545.
310. Dougan L., Feng G., Lu H., Fernandez J.M. Solvent molecules bridge the mechanical unfolding transition state of a protein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3185-3190.
311. Yuan J.M., Chyan C.L., Zhou H.X., Chung T.Y., Peng H., Ping G., Yang G. The effects of macromolecular crowding on the mechanical stability of protein molecules. Protein Sci. 2008, 17:2156-2166.
312. Cao Y., Li H. How do chemical denaturants affect the mechanical folding and unfolding of proteins?. J. Mol. Biol. 2008, 375:316-324.
313. Ma L., Xu M., Oberhauser A.F. Naturally occurring osmolytes modulate the nanomechanical properties of polycystic kidney disease domains. J. Biol. Chem. 2010, 285:38438-38443.
314. Das U., Hariprasad G., Ethayathulla A.S., Manral P., Das T.K., Pasha S., Mann A., Ganguli M., Verma A.K., Bhat R., Chandrayan S.K., Ahmed S., Sharma S., Kaur P., Singh T.P., Srinivasan A. Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key. PLoS One 2007, 2:e1176.
315. Bam N.B., Randolph T.W., Cleland J.L. Stability of protein formulations: investigation of surfactant effects by a novel EPR spectroscopic technique. Pharm. Res. 1995, 12:2-11.
316. Jones L.S., Cipolla D., Liu J., Shire S.J., Randolph T.W. Investigation of protein-surfactant interactions by analytical ultracentrifugation and electron paramagnetic resonance: the use of recombinant human tissue factor as an example. Pharm. Res. 1999, 16:808-812.
317. Basumallick L., Ji J.A., Naber N., Wang Y.J. The fate of free radicals in a cellulose based hydrogel: detection by electron paramagnetic resonance spectroscopy. J. Pharm. Sci. 2009, 98:2464-2471.
318. Eastoe J., Dalton J.S. Dynamic surface tension and adsorption mechanisms of surfactants at the air-water interface. Adv. Colloid Interface Sci. 2000, 85:103-144.
319. Jung J.M., Gunes D.Z., Mezzenga R. Interfacial activity and interfacial shear rheology of native beta-lactoglobulin monomers and their heat-induced fibers. Langmuir 2010, 26:15366-15375.
320. Pradines V., Fainerman V.B., Aksenenko E.V., Kragel J., Wustneck R., Miller R. Adsorption of protein-surfactant complexes at the water/oil interface. Langmuir 2011, 27:965-971.
321. De Feijter J., Benjamins J.A., Veer F. Ellipsometry as a tool to study the adsorption behavior of synthetic and biopolymers at the air-water interface. Biopolymers 1978, 17:1759-1772.
322. Zhmud B., Tiberg F. Interfacial dynamics and structure of surfactant layers. Adv. Colloid Interface Sci. 2005, 113:21-42.
323. Lu J.R. Neutron reflection studies of interactions between surfactants and proteins at interfaces. Annu. Rep. Prog. Chem. C: Phys. Chem. 2002, 98:2-32.
324. Lu J.R., Thomas R.K., Penfold J. Surfactant layers at the air/water interface: structure and composition. Adv. Colloid Interface Sci. 2000, 84:143-304.
325. Lu J.R., Zhao X., Yaseen M. Protein adsorption studied by neutron reflection. Curr. Opin. Colloid Interface Sci. 2007, 12:9-16.
326. Hayter J.B., Highfield R.R., Pullman B.J., Thomas R.K., McMullen A.I., Penfold J. Critical reflection of neutrons. A new technique for investigating interfacial phenomena. J. Chem. Soc., Faraday Trans. 1 F 1981, 77:1437-1448.
327. Lad M.D., Birembaut F., Matthew J.M., Frazier R.A., Green R.J. The adsorbed conformation of globular proteins at the air/water interface. Phys. Chem. Chem. Phys. 2006, 8:2179-2186.
328. Lad M.D., Birembaut F., Frazier R.A., Green R.J. Protein-lipid interactions at the air/water interface. Phys. Chem. Chem. Phys. 2005, 7:3478-3485.
329. Thompson N.L., Axelrod D. Immunoglobulin surface-binding kinetics studied by total internal reflection with fluorescence correlation spectroscopy. Biophys. J. 1983, 43:103-114.
330. Thompson N.L., Burghardt T.P., Axelrod D. Measuring surface dynamics of biomolecules by total internal reflection fluorescence with photobleaching recovery or correlation spectroscopy. Biophys. J. 1981, 33:435-454.
331. Sonesson A.W., Blom H., Hassler K., Elofsson U.M., Callisen T.H., Widengren J., Brismar H. Protein-surfactant interactions at hydrophobic interfaces studied with total internal reflection fluorescence correlation spectroscopy (TIR-FCS). J. Colloid Interface Sci. 2008, 317:449-457.
332. Donoho D.L., Grimes C. Hessian eigenmaps: locally linear embedding techniques for high-dimensional data. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5591-5596.
333. Mugavin M.E. Multidimensional scaling: a brief overview. Nurs. Res. 2008, 57:64-68.
334. Cox T.F., Cox M.A. Multidimensional Scaling 2001, Chapman and Hall/CRC, Boca Raton. 2nd ed.
335. Roweis S.T., Saul L.K. Nonlinear dimensionality reduction by locally linear embedding. Science 2000, 290:2323-2326.
336. Kohonen T., Somervuo P. How to make large self-organizing maps for nonvectorial data. Neural Netw. 2002, 15:945-952.
337. Kohonen T., Oja E. Computing with neural networks. Science 1987, 235:1227a.
338. Theodoridis S., Koutroumbas K. Pattern Recognition 2009, Academic Press/Elsevier, London. 4th ed.
339. Noda I., Ozaki Y. Two-dimensional Correlation Spectroscopy: Applications in Vibrational and Optical Spectroscopy 2004, J. Wiley, Hoboken, N.J.
340. Noda I. Two-dimensional infrared (2D IR) spectroscopy: theory and applications. Appl. Spectrosc. 1990, 44:550-561.
341. Noda I. Bull. Am. Phys. Soc. 1986, 31:520.
342. Kamerzell T.J., Li M., Arora S., Ji J.A., Wang Y.J. The relative rate of immunoglobulin gamma 1 fragmentation. J. Pharm. Sci. 2011, 100:1341-1349.
343. Jolliffe I.T. Principal Component Analysis 2004, Springer, New York. 2nd ed.
344. Butt H.J. Measuring electrostatic, van der Waals, and hydration forces in electrolyte solutions with an atomic force microscope. Biophys. J. 1991, 60:1438-1444.
345. Butt H.J. Electrostatic interaction in atomic force microscopy. Biophys. J. 1991, 60:777-785.
346. Merchant K.A., Thompson D.E., Xu Q.H., Williams R.B., Loring R.F., Fayer M.D. Myoglobin-CO conformational substate dynamics: 2D vibrational echoes and MD simulations. Biophys. J. 2002, 82:3277-3288.
347. DeCamp M.F., DeFlores L., McCracken J.M., Tokmakoff A., Kwac K., Cho M. Amide I vibrational dynamics of N-methylacetamide in polar solvents: the role of electrostatic interactions. J. Phys. Chem. B 2005, 109:11016-11026.
348. Sinensky A.K., Belcher A.M. Label-free and high-resolution protein/DNA nanoarray analysis using Kelvin probe force microscopy. Nat. Nanotechnol. 2007, 2:653-659.
349. Leung C., Kinns H., Hoogenboom B.W., Howorka S., Mesquida P. Imaging surface charges of individual biomolecules. Nano Lett. 2009, 9:2769-2773.
350. Matulis D., Rouzina I., Bloomfield V.A. Thermodynamics of DNA binding and condensation: isothermal titration calorimetry and electrostatic mechanism. J. Mol. Biol. 2000, 296:1053-1063.
351. Vogel R. Influence of salts on rhodopsin photoproduct equilibria and protein stability. Curr. Opin. Colloid Interface Sci. 2004, 9:133-138.
352. Durant J.A., Chen C., Laue T.M., Moody T.P., Allison S.A. Use of T4 lysozyme charge mutants to examine electrophoretic models. Biophys. Chem. 2002, 101-102:593-609.
353. Hunt N.T., Jaye A.A., Meech S.R. Ultrafast dynamics in complex fluids observed through the ultrafast optically-heterodyne-detected optical-Kerr-effect (OHD-OKE). Phys. Chem. Chem. Phys. 2007, 9:2167-2180.
354. Boxer S.G. Stark realities. J. Phys. Chem. B 2009, 113:2972-2983.
355. Khadjavi A. Electric-field level-crossing spectroscopy. Phys. Rev. Lett. 1966, 17:463-465.
356. Zare R.N. Molecular level-crossing spectroscopy. J. Chem. Phys. 1966, 45:4510-4518.
357. Richmond G.L. Molecular bonding and interactions at aqueous surfaces as probed by vibrational sum frequency spectroscopy. Chem. Rev. 2002, 102:2693-2724.
358. Baldwin R.L. How Hofmeister ion interactions affect protein stability. Biophys. J. 1996, 71:2056-2063.
359. Bakker H.J. Water dynamics: ion-ing out the details. Nat. Chem. 2009, 1:24-25.
360. Omta A.W., Kropman M.F., Woutersen S., Bakker H.J. Negligible effect of ions on the hydrogen-bond structure in liquid water. Science 2003, 301:347-349.
361. Tielrooij K.J., Garcia-Araez N., Bonn M., Bakker H.J. Cooperativity in ion hydration. Science 2010, 328:1006-1009.
362. Gokarn Y.R., Fesinmeyer R.M., Saluja A., Cao S., Dankberg J., Goetze A., Remmele R.L., Narhi L.O., Brems D.N. Ion-specific modulation of protein interactions: anion-induced, reversible oligomerization of a fusion protein. Protein Sci. 2009, 18:169-179.
363. Volkin D.B., Verticelli A.M., Marfia K.E., Burke C.J., Mach H., Middaugh C.R. Sucralfate and soluble sucrose octasulfate bind and stabilize acidic fibroblast growth factor. Biochim. Biophys. Acta 1993, 1203:18-26.
364. Burke C.J., Volkin D.B., Mach H., Middaugh C.R. Effect of polyanions on the unfolding of acidic fibroblast growth factor. Biochemistry 1993, 32:6419-6426.
365. Shukla D., Trout B.L. Preferential interaction coefficients of proteins in aqueous arginine solutions and their molecular origins. J. Phys. Chem. B 2011, 115:1243-1253.
366. Ma J.C., Dougherty D.A. The cation-pi interaction. Chem. Rev. 1997, 97:1303-1324.
367. Dougherty D.A. Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science 1996, 271:163-168.
368. Gallivan J.P., Dougherty D.A. Cation-pi interactions in structural biology. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9459-9464.
369. Sorme P., Arnoux P., Kahl-Knutsson B., Leffler H., Rini J.M., Nilsson U.J. Structural and thermodynamic studies on cation-pi interactions in lectin-ligand complexes: high-affinity galectin-3 inhibitors through fine-tuning of an arginine-arene interaction. J. Am. Chem. Soc. 2005, 127:1737-1743.
370. Ishibashi M., Tsumoto K., Tokunaga M., Ejima D., Kita Y., Arakawa T. Is arginine a protein-denaturant?. Protein Expr. Purif. 2005, 42:1-6.
371. Baynes B.M., Wang D.I., Trout B.L. Role of arginine in the stabilization of proteins against aggregation. Biochemistry 2005, 44:4919-4925.
372. Crowley P.B., Golovin A. Cation-pi interactions in protein-protein interfaces. Proteins 2005, 59:231-239.
373. Lee J.C., Gekko K., Timasheff S.N. Measurements of preferential solvent interactions by densimetric techniques. Methods Enzymol. 1979, 61:26-49.
374. Lee J.C., Timasheff S.N. Partial specific volumes and interactions with solvent components of proteins in guanidine hydrochloride. Biochemistry 1974, 13:257-265.
375. Smith P.E. Chemical potential derivatives and preferential interaction parameters in biological systems from Kirkwood-Buff theory. Biophys. J. 2006, 91:849-856.
376. Schellman J.A. Protein stability in mixed solvents: a balance of contact interaction and excluded volume. Biophys. J. 2003, 85:108-125.
377. Timasheff S.N. Protein-solvent preferential interactions, protein hydration, and the modulation of biochemical reactions by solvent components. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:9721-9726.
378. Parsegian V.A., Rand R.P., Rau D.C. Osmotic stress, crowding, preferential hydration, and binding: a comparison of perspectives. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3987-3992.
379. Aune K.C., Tanford C. Thermodynamics of the denaturation of lysozyme by guanidine hydrochloride. II. Dependence on denaturant concentration at 25 degrees. Biochemistry 1969, 8:4586-4590.
380. Schneider C.P., Shukla D., Trout B.L. Arginine and the hofmeister series: the role of ion-ion interactions in protein aggregation suppression. J. Phys. Chem. B 2011, 115:7447-7458.
381. Schneider C.P., Trout B.L. Investigation of cosolute-protein preferential interaction coefficients: new insight into the mechanism by which arginine inhibits aggregation. J. Phys. Chem. B 2009, 113:2050-2058.
382. Linhananta A., Hadizadeh S., Plotkin S.S. An effective solvent theory connecting the underlying mechanisms of osmolytes and denaturants for protein stability. Biophys. J. 2011, 100:459-468.
383. Street T.O., Bolen D.W., Rose G.D. A molecular mechanism for osmolyte-induced protein stability. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13997-14002.
384. Zou Q., Bennion B.J., Daggett V., Murphy K.P. The molecular mechanism of stabilization of proteins by TMAO and its ability to counteract the effects of urea. J. Am. Chem. Soc. 2002, 124:1192-1202.
385. Rezus Y.L., Bakker H.J. Destabilization of the hydrogen-bond structure of water by the osmolyte trimethylamine N-oxide. J. Phys. Chem. B 2009, 113:4038-4044.
386. Panuszko A., Bruzdziak P., Zielkiewicz J., Wyrzykowski D., Stangret J. Effects of urea and trimethylamine-N-oxide on the properties of water and the secondary structure of hen egg white lysozyme. J. Phys. Chem. B 2009, 113:14797-14809.
387. Vagenende V., Yap M.G., Trout B.L. Molecular anatomy of preferential interaction coefficients by elucidating protein solvation in mixed solvents: methodology and application for lysozyme in aqueous glycerol. J. Phys. Chem. B 2009, 113:11743-11753.
388. Bostrom M., Williams D.R., Ninham B.W. Specific ion effects: why the properties of lysozyme in salt solutions follow a Hofmeister series. Biophys. J. 2003, 85:686-694.
389. Hua L., Zhou R., Thirumalai D., Berne B.J. Urea denaturation by stronger dispersion interactions with proteins than water implies a 2-stage unfolding. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16928-16933.
390. del Carmen Fernandez-Alonso M., Canada F.J., Jimenez-Barbero J., Cuevas G. Molecular recognition of saccharides by proteins. Insights on the origin of the carbohydrate-aromatic interactions. J. Am. Chem. Soc. 2005, 127:7379-7386.
391. Roth C.M., Neal B.L., Lenhoff A.M. Van der Waals interactions involving proteins. Biophys. J. 1996, 70:977-987.
392. Fowkes F.M. Additivity of intermolecular forces at interfaces. I. Determination of the contribution to surface and interfacial tensions of dispersion forces in various liquids. J. Phys. Chem. 1963, 67:2538-2541.
393. French R.H. Origins and applications of London dispersion forces and hamaker constants in ceramics. J. Am. Ceram. Soc. 2000, 83:2117-2146.
394. Roth C.M., Lenhoff A.M. Electrostatic and van der Waals contributions to protein adsorption: comparison of theory and experiment. Langmuir 1995, 11:3500-3509.
395. Ewing G.E. Structure and properties of van der Waals molecules. Acc. Chem. Res. 1975, 8:185-192.
396. McHale J.L. Molecular Spectroscopy 1999, Prentice Hall, Upper Saddle River. 1st ed.
397. Wei H., Fan Y., Gao Y.Q. Effects of urea, tetramethyl urea, and trimethylamine N-oxide on aqueous solution structure and solvation of protein backbones: a molecular dynamics simulation study. J. Phys. Chem. B 2010, 114:557-568.
398. Zangi R., Zhou R., Berne B.J. Urea's action on hydrophobic interactions. J. Am. Chem. Soc. 2009, 131:1535-1541.
399. Parsons D.F., Bostrom M., Maceina T.J., Salis A., Ninham B.W. Why direct or reversed Hofmeister series? Interplay of hydration, non-electrostatic potentials, and ion size. Langmuir 2010, 26:3323-3328.
400. Bostrom M., Tavares F.W., Finet S., Skouri-Panet F., Tardieu A., Ninham B.W. Why forces between proteins follow different Hofmeister series for pH above and below pI. Biophys. Chem. 2005, 117:217-224.
401. Bostrom M., Tavares F.W., Bratko D., Ninham B.W. Specific ion effects in solutions of globular proteins: comparison between analytical models and simulation. J. Phys. Chem. B 2005, 109:24489-24494.
402. Bostrom M., Kunz W., Ninham B.W. Hofmeister effects in surface tension of aqueous electrolyte solution. Langmuir 2005, 21:2619-2623.
403. Sujatha M.S., Sasidhar Y.U., Balaji P.V. Energetics of galactose- and glucose-aromatic amino acid interactions: implications for binding in galactose-specific proteins. Protein Sci. 2004, 13:2502-2514.
404. Sujatha M.S., Sasidhar Y.U., Balaji P.V. Insights into the role of the aromatic residue in galactose-binding sites: MP2/6-311G++** study on galactose- and glucose-aromatic residue analogue complexes. Biochemistry 2005, 44:8554-8562.
405. Terraneo G., Potenza D., Canales A., Jimenez-Barbero J., Baldridge K.K., Bernardi A. A simple model system for the study of carbohydrate-aromatic interactions. J. Am. Chem. Soc. 2007, 129:2890-2900.
406. Stanca-Kaposta E.C., Gamblin D.P., Screen J., Liu B., Snoek L.C., Davis B.G., Simons J.P. Carbohydrate molecular recognition: a spectroscopic investigation of carbohydrate-aromatic interactions. Phys. Chem. Chem. Phys. 2007, 9:4444-4451.
407. Toone E.J. Structure and energetics of protein-carbohydrate complexes. Curr. Opin. Struct. Biol. 1994, 4:719-728.
408. Elgavish S., Shaanan B. Lectin-carbohydrate interactions: different folds, common recognition principles. Trends Biochem. Sci. 1997, 22:462-467.
409. Li X.Z., Walker B., Michaelides A. Quantum nature of the hydrogen bond. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:6369-6373.
410. Martin Pendas A., Blanco M.A., Francisco E. The nature of the hydrogen bond: a synthesis from the interacting quantum atoms picture. J. Chem. Phys. 2006, 125:184112.
411. Kollman P.A., Allen L.C. The theory of the hydrogen bond. Chem. Rev. 1972, 72:283-303.
412. Walrafen G.E., Fisher M. Low frequency Raman scattering from water and aqueous solution: a direct measure of hydrogen bonding. Methods Enzymol. 1986, 127:91-105.
413. Savage H., Wlodawer A. Determination of water structure around biomolecules using X-ray and neutron diffraction methods. Methods Enzymol. 1986, 127:162-183.
414. Grzesiek S., Cordier F., Dingley A.J. Scalar couplings across hydrogen bonds. Methods Enzymol. 2001, 338:111-133.
415. Hoofnagle A.N., Resing K.A., Ahn N.G. Protein analysis by hydrogen exchange mass spectrometry. Annu. Rev. Biophys. Biomol. Struct. 2003, 32:1-25.
416. Carpenter J.F., Crowe J.H. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 1989, 28:3916-3922.
417. Carpenter J.F., Crowe J.H. The mechanism of cryoprotection of proteins by solutes. Cryobiology 1988, 25:244-255.
418. Carpenter J.F., Crowe L.M., Crowe J.H. Stabilization of phosphofructokinase with sugars during freeze-drying: characterization of enhanced protection in the presence of divalent cations. Biochim. Biophys. Acta 1987, 923:109-115.
419. Carpenter J.F., Martin B., Crowe L.M., Crowe J.H. Stabilization of phosphofructokinase during air-drying with sugars and sugar/transition metal mixtures. Cryobiology 1987, 24:455-464.
420. Carpenter J.F., Martin B., Loomis S.H., Crowe J.H. Long-term preservation of dried phosphofructokinase by sugars and sugar/zinc mixtures. Cryobiology 1988, 25:372-376.
421. Prestrelski S.J., Tedeschi N., Arakawa T., Carpenter J.F. Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys. J. 1993, 65:661-671.
422. Allison S.D., Chang B., Randolph T.W., Carpenter J.F. Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding. Arch. Biochem. Biophys. 1999, 365:289-298.
423. Allison S.D., Manning M.C., Randolph T.W., Middleton K., Davis A., Carpenter J.F. Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran. J. Pharm. Sci. 2000, 89:199-214.
424. Imamura K., Ogawa T., Sakiyama T., Nakanishi K. Effects of types of sugar on the stabilization of protein in the dried state. J. Pharm. Sci. 2003, 92:266-274.
425. Glaudemans C.P., Kovac P., Nashed E.M. Mapping of hydrogen bonding between saccharides and proteins in solution. Methods Enzymol. 1994, 247:305-322.
426. Qvist J., Halle B. Thermal signature of hydrophobic hydration dynamics. J. Am. Chem. Soc. 2008, 130:10345-10353.
427. Batchelor J.D., Olteanu A., Tripathy A., Pielak G.J. Impact of protein denaturants and stabilizers on water structure. J. Am. Chem. Soc. 2004, 126:1958-1961.
428. Harries D., Rosgen J. A practical guide on how osmolytes modulate macromolecular properties. Methods Cell Biol. 2008, 84:679-735.
429. Krywka C., Sternemann C., Paulus M., Tolan M., Royer C., Winter R. Effect of osmolytes on pressure-induced unfolding of proteins: a high-pressure SAXS study. Chemphyschem 2008, 9:2809-2815.
430. Anchordoquy T.J., Izutsu K.I., Randolph T.W., Carpenter J.F. Maintenance of quaternary structure in the frozen state stabilizes lactate dehydrogenase during freeze-drying. Arch. Biochem. Biophys. 2001, 390:35-41.
431. Shire S.J., Shahrokh Z., Liu J. Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 2004, 93:1390-1402.
432. Salinas B.A., Sathish H.A., Bishop S.M., Harn N., Carpenter J.F., Randolph T.W. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J. Pharm. Sci. 2010, 99:82-93.
433. Dumetz A.C., Chockla A.M., Kaler E.W., Lenhoff A.M. Protein phase behavior in aqueous solutions: crystallization, liquid-liquid phase separation, gels, and aggregates. Biophys. J. 2008, 94:570-583.
434. Papon P., Leblond J., Meijer P. The Physics of Phase Transitions 2006, Springer-Verlag, Berlin Heidelberg.
435. Chaikin P.M., lubensky T.C. Principles of Condensed Matter Physics 1995, Cambridge University Press, Cambridge.
436. Jones R.A.L. Soft Condensed Matter 2002, Oxford University Press, New York.
437. Dong J., Hubel A., Bischof J.C., Aksan A. Freezing-induced phase separation and spatial microheterogeneity in protein solutions. J. Phys. Chem. B 2009, 113:10081-10087.
438. Voth G.A. Coarse-Graining of Condensed Phase and Biomolecular Systems 2009, CRC Press, Boca Raton.
439. Strambini G.B., Gabellieri E. Intrinsic phosphorescence from proteins in the solid state. Photochem. Photobiol. 1984, 39:725-729.
440. Strambini G.B., Gabellieri E. Phosphorescence anisotropy of liver alcohol dehydrogenase in the crystalline state. Apparent glasslike rigidity of the coenzyme-binding domain. Biochemistry 1987, 26:6527-6530.
441. Stradner A., Cardinaux F., Schurtenberger P. A small-angle scattering study on equilibrium clusters in lysozyme solutions. J. Phys. Chem. B 2006, 110:21222-21231.
442. Stradner A., Sedgwick H., Cardinaux F., Poon W.C., Egelhaaf S.U., Schurtenberger P. Equilibrium cluster formation in concentrated protein solutions and colloids. Nature 2004, 432:492-495.
443. Connolly B., Patapoff T.W., Wang Y.J., Moore J.M., Kamerzell T.J. Vibrational spectroscopy and chemometrics to characterize and quantitate trehalose crystallization. Anal. Biochem. 2010, 399:48-57.
444. Lu P.J., Zaccarelli E., Ciulla F., Schofield A.B., Sciortino F., Weitz D.A. Gelation of particles with short-range attraction. Nature 2008, 453:499-503.
445. Lu P.J., Conrad J.C., Wyss H.M., Schofield A.B., Weitz D.A. Fluids of clusters in attractive colloids. Phys. Rev. Lett. 2006, 96:028306.
446. Shukla A., Mylonas E., Di Cola E., Finet S., Timmins P., Narayanan T., Svergun D.I. Absence of equilibrium cluster phase in concentrated lysozyme solutions. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5075-5080.
447. Porcar L., Falus P., Chen W.F., Faraone A., Fratini E., Hong K., Baglioni P., Liu Y. Formation of the dynamic clusters in concentrated lysozyme protein solutions. J. Phys. Chem. Lett. 2010, 1:126-129.
448. Andya J.D., Maa Y.F., Costantino H.R., Nguyen P.A., Dasovich N., Sweeney T.D., Hsu C.C., Shire S.J. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm. Res. 1999, 16:350-358.
449. Arakawa T., Prestrelski S.J., Kenney W.C., Carpenter J.F. Factors affecting short-term and long-term stabilities of proteins. Adv. Drug Deliv. Rev. 2001, 46:307-326.
450. Tang X.C., Pikal M.J. The effect of stabilizers and denaturants on the cold denaturation temperatures of proteins and implications for freeze-drying. Pharm. Res. 2005, 22:1167-1175.
451. Carpenter J.F., Crowe J.H., Arakawa T. Comparison of solute-induced protein stabilization in aqueous solution and in the frozen and dried states. J. Dairy Sci. 1990, 73:3627-3636.
452. Heller M.C., Carpenter J.F., Randolph T.W. Effects of phase separating systems on lyophilized hemoglobin. J. Pharm. Sci. 1996, 85:1358-1362.
453. Randolph T.W. Phase separation of excipients during lyophilization: effects on protein stability. J. Pharm. Sci. 1997, 86:1198-1203.
454. 2O on pH and composition during freezing. Arch. Biochem. Biophys. 1959, 84:305-315.
455. 2O. Arch. Biochem. Biophys. 1959, 81:319-329.
456. Izutsu K., Yoshioka S., Terao T. Decreased protein-stabilizing effects of cryoprotectants due to crystallization. Pharm. Res. 1993, 10:1232-1237.
457. Privalov P.L. Cold denaturation of proteins. Crit. Rev. Biochem. Mol. Biol. 1990, 25:281-305.
458. Strambini G.B., Gabellieri E. Proteins in frozen solutions: evidence of ice-induced partial unfolding. Biophys. J. 1996, 70:971-976.
459. Strambini G.B., Gonnelli M. Protein stability in ice. Biophys. J. 2007, 92:2131-2138.
460. Crowe L.M., Reid D.S., Crowe J.H. Is trehalose special for preserving dry biomaterials?. Biophys. J. 1996, 71:2087-2093.
461. Tumerman L., Fram H., Cornely K.W. The effect of lactose crystallization on protein stability in frozen concentrated milk. J. Dairy Sci. 1954, 37:830-839.
462. Strambini G.B., Gonnelli M. Specific anions effects of on the stability of azurin in ice. J. Phys. Chem. B 2008, 112:10255-10263.
463. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid State Chemistry of Drugs 1999, SSCI, Inc., West Lafeyette.
464. Sukumar M., Doyle B.L., Combs J.L., Pekar A.H. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm. Res. 2004, 21:1087-1093.
465. Woods J., Nesta D. Formulation effects on opalescence of a high-concentration MAb. BioProcess Int. 2010, 8:48-59.
466. Mason B.D., Zhang L., Remmele R.L., Zhang J. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation. J. Pharm. Sci. 2011, 100:4587-4596.
467. Sharma D.K., Oma P., Pollo M.J., Sukumar M. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging. J. Pharm. Sci. 2010, 99:2628-2642.
468. Eckhardt B.M., Oeswein J.Q., Bewley T.A. Effect of freezing on aggregation of human growth hormone. Pharm. Res. 1991, 8:1360-1364.
469. Eckhardt B.M., Oeswein J.Q., Yeung D.A., Milby T.D., Bewley T.A. A turbidimetric method to determine visual appearance of protein solutions. J. Pharm. Sci. Technol. 1994, 48:64-70.
470. Pearlman R., Bewley T.A. Stability and characterization of human growth hormone. Pharm. Biotechnol. 1993, 5:1-58.
471. Hsu C.C., Nguyen H.M., Yeung D.A., Brooks D.A., Koe G.S., Bewley T.A., Pearlman R. Surface denaturation at solid-void interface-a possible pathway by which opalescent particulates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures. Pharm. Res. 1995, 12:69-77.
472. Cromwell M. Opalescence in antibody formulations is a solution critical phenomenon. The 236th ACS National Meeting 2008, Philadelphia, PA.
473. Wang N., Hu B., Ionescu R., Mach H., Sweeney J., Hamm C., Kirchmeier M.J., Meyer B.K. Opalescence of an IgG1 monoclonal antibody formulation is mediated by ionic strength and excipients. BioPharm. Int. 2009, 22.
474. Nishi H., Miyajima M., Nakagami H., Noda M., Uchiyama S., Fukui K. Phase separation of an IgG1 antibody solution under a low ionic strength condition. Pharm. Res. 2010, 27:1348-1360.
475. Mason B.D., Zhang-van Enk J., Zhang L., Remmele R.L., Zhang J. Liquid-liquid phase separation of a monoclonal antibody and nonmonotonic influence of Hofmeister anions. Biophys. J. 2010, 99:3792-3800.
476. Lewus R.A., Darcy P.A., Lenhoff A.M., Sandler S.I. Interactions and phase behavior of a monoclonal antibody. Biotechnol. Prog. 2011, 27:280-289.
477. Ahamed T., Esteban B.N., Ottens M., van Dedem G.W., van der Wielen L.A., Bisschops M.A., Lee A., Pham C., Thommes J. Phase behavior of an intact monoclonal antibody. Biophys. J. 2007, 93:610-619.
478. Annunziata O., Asherie N., Lomakin A., Pande J., Ogun O., Benedek G.B. Effect of polyethylene glycol on the liquid-liquid phase transition in aqueous protein solutions. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14165-14170.
479. Galkin O., Vekilov P.G. Control of protein crystal nucleation around the metastable liquid-liquid phase boundary. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6277-6281.
480. Clark J.I., Benedek G.B. The effects of glycols, aldehydes, and acrylamide on phase separation and opacification in the calf lens. Invest. Ophthalmol. Vis. Sci. 1980, 19:771-776.
481. Taratuta V.G., Holschbach A., Thurston G.M., Blankschtein D., Benedek G.B. Liquid-liquid phase separation of aqueous lysozyme solutions: effects of pH and salt identity. J. Phys. Chem. B 1990, 94:2140-2144.
482. Baier S., McClements D.J. Influence of cosolvent systems on the gelation mechanism of globular protein: thermodynamic, kinetic, and structural aspects of globular protein gelation. Compr. Rev. Food Sci. Food Saf. 2005, 4:43-54.
483. Rich L.M., Foegeding E.A. Effects of sugars on whey protein isolate gelation. J. Agric. Food Chem. 2000, 48:5046-5052.
484. Kendrick B.S., Cleland J.L., Lam X., Nguyen T., Randolph T.W., Manning M.C., Carpenter J.F. Aggregation of recombinant human interferon gamma: kinetics and structural transitions. J. Pharm. Sci. 1998, 87:1069-1076.
485. Aggeli A., Bell M., Boden N., Keen J.N., Knowles P.F., McLeish T.C., Pitkeathly M., Radford S.E. Responsive gels formed by the spontaneous self-assembly of peptides into polymeric beta-sheet tapes. Nature 1997, 386:259-262.
486. Navarra G., Giacomazza D., Leone M., Librizzi F., Militello V., San Biagio P.L. Thermal aggregation and ion-induced cold-gelation of bovine serum albumin. Eur. Biophys. J. 2009, 38:437-446.
487. Boye J.I., Alli I., Ismail A.A. Interactions involved in the gelation of bovine serum albumin. J. Agric. Food Chem. 1996, 44:996-1004.
488. Clark A.H., Saunderson D.H., Suggett A. Infrared and laser-Raman spectroscopic studies of thermally-induced globular protein gels. Int. J. Pept. Protein Res. 1981, 17:353-364.
489. Babajimopoulos M., Damodaran S., Rizvi S., Kinsella J.E. Effects of various anions on the rheological and gelling behavior of soy proteins: thermodynamic observations. J. Agric. Food Chem. 1983, 31:1270-1275.
490. Bowland E.L., Foegeding E.A. Effects of anions on thermally induced whey protein isolate gels. Food Hydrocolloids 1995, 9:47-56.
491. He J.S., Azuma N., Hagiwara T., Kanno C. Effects of sugars on the cross-linking formation and phase separation of high-pressure induced gel of whey protein from bovine milk. Biosci. Biotechnol. Biochem. 2006, 70:615-625.
492. Petka W.A., Harden J.L., McGrath K.P., Wirtz D., Tirrell D.A. Reversible hydrogels from self-assembling artificial proteins. Science 1998, 281:389-392.
493. Gosal W.S. Globular protein gelation. Curr. Opin. Colloid Interface Sci. 2000, 5:188-194.
494. Norde W. Adsorption of proteins from solution at the solid-liquid interface. Adv. Colloid Interface Sci. 1986, 25:267-340.
495. Burke C.J., Steadman B., Volkin D.B., Tsai P.K., Bruner M., Middaugh C.R. The adsorption of proteins to pharmaceutical container surfaces. Int. J. Pharm. 1992, 86:89-93.
496. Maa Y.F., Hsu C.C. Protein denaturation by combined effect of shear and air-liquid interface. Biotechnol. Bioeng. 1997, 54:503-512.
497. Sethuraman A., Belfort G. Protein structural perturbation and aggregation on homogeneous surfaces. Biophys. J. 2005, 88:1322-1333.
498. Rathore N., Rajan R.S. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol. Prog. 2008, 24:504-514.
499. Sharma B. Immunogenicity of therapeutic proteins. Part 2: impact of container closures. Biotechnol. Adv. 2007, 25:318-324.
500. Sadana A. Interfacial protein adsorption and inactivation. Bioseparation 1992, 3:297-320.
501. Colombie S., Gaunand A., Lindet B. Lysozyme inactivation under mechanical stirring: effect of physical and molecular interfaces. Enzyme Microb. Technol. 2001, 28:820-826.
502. Nakanishi K., Sakiyama T., Imamura K. On the adsorption of proteins on solid surfaces, a common but very complicated phenomenon. J. Biosci. Bioeng. 2001, 91:233-244.
503. Bee J.S., Chiu D., Sawicki S., Stevenson J.L., Chatterjee K., Freund E., Carpenter J.F., Randolph T.W. Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. J. Pharm. Sci. 2009, 98:3218-3238.
504. Bagchi P., Birnbaum S.M. Adsorption of catalase on hydroxyapatite. J. Colloid Interface Sci. 1981, 83:460-478.
505. Barroug A., Lernoux E., Lemaitre J., Rouxhet P.G. Adsorption of catalase on hydroxyapatite. J. Colloid Interface Sci. 1998, 208:147-152.
506. Fukuzaki S., Urano H., Nagata K. Adsorption of protein onto stainless-steel surfaces. J. Ferment. Bioeng. 1995, 80:6-11.
507. Luey J., McGuire J., Sproull R. The effect of pH and sodium chloride concentration on adsorption of B-lactoglobulin at hydrophilic and hydrophobic silicon surfaces. J. Colloid Interface Sci. 1991, 143:489-500.
508. Ortega Vinuesa J.L., Hidalgo-Alvarez R. Study of the adsorption of F(ab')2 onto polystyrene latex beads. Colloids Surf. B Biointerfaces 1993, 1:365-372.
509. Serra J., Puig J., Martin A., Galisteo F., Galvez M., Hidalgo-Alvarez R. On the adsorption of IgG onto polystyrene particles: electrophoretic mobility and critical coagulation concentration. Colloid Polym. Sci. 1992, 270:574-583.
510. Wahlgren M.C., Arnebrant T., Paulsson M.A. The adsorption from solutions of beta-lactoblobulin mixed with lactoferrin or lysozyme onto silica and methylated silica surfaces. J. Colloid Interface Sci. 1993, 158:46-53.
511. Buijs J., Norde W., Lichtenbelt J. Changes in the secondary structure of adsorbed IgG and F(ab')2 studied by FTIR spectroscopy. Langmuir 1996, 12:1605-1613.
512. Elgersma A., Zsom R., Lyklema J., Norde W. Adsorption competition between albumin and monoclonal immunogammaglobulins on polystyrene latexes. J. Colloid Interface Sci. 1992, 152:410-428.
513. Van der Vegt W., Van der Mei H.C., Busscher H.J. Interfacial free energies in protein solution droplets on FEP-teflon by axisymmetric drop shape analysis by profile-IgG versus BSA. J. Colloid Interface Sci. 1993, 156:129-136.
514. Wendorf J.R., Radke C.J., Blanch H.W. The role of electrolytes on protein adsorption at a hydrophilic solid-water interface. Colloids Surf. B Biointerfaces 2010, 75:100-106.
515. Wei T., Kaewtathip S., Shing K. Buffer effect on protein adsorption at liquid/solid interface. J. Phys. Chem. C 2009, 113:2053-2062.
516. Patro S.Y., Freund E., Chang B.S. Protein formulation and fill-finish operations. Biotechnol. Annu. Rev. 2002, 8:55-84.
517. Jones L., Bam N.B., Randolph T.W. Surfactant stabilized protein formulations: a review of protein-surfactant interactions and novel analytical methodologies. Therapeutic Protein and Peptide Formulation and Delivery 1997, American Chemical Society.
518. Jones M. Surface Activity of Proteins: Chemical and Physicochemical Modifications 1996, M. Dekker, New York.
519. Miller R., Fainerman V.B., Makievski A.V., Kragel J., Grigoriev D.O., Kazakov V.N., Sinyachenko O.V. Dynamics of protein and mixed protein/surfactant adsorption layers at the water/fluid interface. Adv. Colloid Interface Sci. 2000, 86:39-82.
520. Chi E.Y., Weickmann J., Carpenter J.F., Manning M.C., Randolph T.W. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J. Pharm. Sci. 2005, 94:256-274.
521. Chou D.K., Krishnamurthy R., Randolph T.W., Carpenter J.F., Manning M.C. Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. J. Pharm. Sci. 2005, 94:1368-1381.
522. Duncan M.R., Lee J.M., Warchol M.P. Influence of surfactants upon protein/peptide adsorption to glass and polypropylene. Int. J. Pharm. 1995, 120:179-188.
523. Kiese S., Papppenberger A., Friess W., Mahler H.C. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J. Pharm. Sci. 2008, 97:4347-4366.
524. Mahler H.C., Mueller R., Friess W., Delille A., Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur. J. Pharm. Biopharm. 2005, 59:407-417.
525. Patapoff T.W., Esue O. Polysorbate 20 prevents the precipitation of a monoclonal antibody during shear. Pharm. Dev. Technol. 2009, 14:659-664.
526. Hoffmann C., Blume A., Miller I., Garidel P. Insights into protein-polysorbate interactions analysed by means of isothermal titration and differential scanning calorimetry. Eur. Biophys. J. 2009, 38:557-568.
527. Nielsen A.D., Arleth L., Westh P. Analysis of protein-surfactant interactions-a titration calorimetric and fluorescence spectroscopic investigation of interactions between Humicola insolens cutinase and an anionic surfactant. Biochim. Biophys. Acta 2005, 1752:124-132.
528. Garidel P., Hoffmann C., Blume A. A thermodynamic analysis of the binding interaction between polysorbate 20 and 80 with human serum albumins and immunoglobulins: a contribution to understand colloidal protein stabilisation. Biophys. Chem. 2009, 143:70-78.
529. Mackie A., Gunning A.P., Wilde P., Morris V.J. Orogenic displacement of protein from the air/water interface by competitive adsorption. J. Colloid Interface Sci. 1999, 210:157-166.
530. Gunning P.A., Mackie A.R., Gunning A.P., Woodward N.C., Wilde P.J., Morris V.J. Effect of surfactant type on surfactant-protein interactions at the air-water interface. Biomacromolecules 2004, 5:984-991.
531. Wendorf J.R., Radke C.J., Blanch H.W. Reduced protein adsorption at solid interfaces by sugar excipients. Biotechnol. Bioeng. 2004, 87:565-573.
532. Tyagi A.K., Randolph T.W., Dong A., Maloney K.M., Hitscherich C., Carpenter J.F. IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles. J. Pharm. Sci. 2009, 98:94-104.
533. Bee J.S., Nelson S.A., Freund E., Carpenter J.F., Randolph T.W. Precipitation of a monoclonal antibody by soluble tungsten. J. Pharm. Sci. 2009, 98:3290-3301.
534. Tzannis S.T., Hrushesky W., Wood P., Przybycien T.M. Adsorption of a formulated protein on a drug delivery device surface. J. Colloid Interface Sci. 1997, 189:216-228.
535. Thirumangalathu R., Krishnan S., Ricci M.S., Brems D.N., Randolph T.W., Carpenter J.F. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J. Pharm. Sci. 2009, 98:3167-3181.
536. Jones L.S., Kaufmann A., Middaugh C.R. Silicone oil induced aggregation of proteins. J. Pharm. Sci. 2005, 94:918-927.
537. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 2007, 5:505-517.
538. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 2009, 98:1278-1316.
539. Hem S.L., White J.L. Structure and properties of aluminum-containing adjuvants. Pharm. Biotechnol. 1995, 6:249-276.
540. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998, 32:155-172.
541. Hogenesch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 20(Suppl. 3):S34-S39.
542. Vogel F.R., Powell M.F. A compendium of vaccine adjuvants and excipients. Pharm. Biotechnol. 1995, 6:141-228.
543. Berthold I., Pombo M.L., Wagner L., Arciniega J.L. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 2005, 23:1993-1999.
544. Romero Mendez I.Z., Shi Y., HogenEsch H., Hem S.L. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007, 25:825-833.
545. al-Shakhshir R.H., Regnier F.E., White J.L., Hem S.L. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1995, 13:41-44.
546. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines 2007, 6:685-698.
547. Iyer S., Robinett R.S., HogenEsch H., Hem S.L. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine 2004, 22:1475-1479.
548. Morefield G.L., Jiang D., Romero-Mendez I.Z., Geahlen R.L., Hogenesch H., Hem S.L. Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. Vaccine 2005, 23:1502-1506.
549. Seeber S.J., White J.L., Hem S.L. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1991, 9:201-203.
550. Jones L.S., Peek L.J., Power J., Markham A., Yazzie B., Middaugh C.R. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem. 2005, 280:13406-13414.
551. Tleugabulova D., Falcon V., Penton E. Evidence for the denaturation of recombinant hepatitis B surface antigen on aluminium hydroxide gel. J. Chromatogr. B Biomed. Sci. Appl. 1998, 720:153-163.
552. Vessely C., Estey T., Randolph T.W., Henderson I., Cooper J., Nayar R., Braun L.J., Carpenter J.F. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J. Pharm. Sci. 2009, 98:2970-2993.
553. Ausar S.F., Chan J., Hoque W., James O., Jayasundara K., Harper K. Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines. J. Pharm. Sci. 2011, 100:431-440.
554. Peek L.J., Brey R.N., Middaugh C.R. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J. Pharm. Sci. 2007, 96:44-60.
555. Salnikova M.S., Joshi S.B., Rytting J.H., Warny M., Middaugh C.R. Preformulation studies of Clostridium difficile toxoids A and B. J. Pharm. Sci. 2008, 97:4194-4207.
556. Bai S., Dong A. Effects of immobilization onto aluminum hydroxide particles on the thermally induced conformational behavior of three model proteins. Int. J. Biol. Macromol. 2009, 45:80-85.
557. Dong A., Jones L.S., Kerwin B.A., Krishnan S., Carpenter J.F. Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations. Anal. Biochem. 2006, 351:282-289.
558. Wittayanukulluk A., Jiang D., Regnier F.E., Hem S.L. Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. Vaccine 2004, 22:1172-1176.
559. Clapp T., Siebert P., Chen D., Jones Braun L. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J. Pharm. Sci. 2011, 100:388-401.